<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8000418</article-id><article-id pub-id-type="pmid">33805830</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics13030387</article-id><article-id pub-id-type="publisher-id">pharmaceutics-13-00387</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Excipients in the Paediatric Population: A Review</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rouaz</surname><given-names>Khadija</given-names></name><xref ref-type="aff" rid="af1-pharmaceutics-13-00387">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9279-536X</contrib-id><name><surname>Chiclana-Rodr&#x000ed;guez</surname><given-names>Blanca</given-names></name><xref ref-type="aff" rid="af1-pharmaceutics-13-00387">1</xref><xref rid="c1-pharmaceutics-13-00387" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9548-3903</contrib-id><name><surname>Nardi-Ricart</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="af1-pharmaceutics-13-00387">1</xref></contrib><contrib contrib-type="author"><name><surname>Su&#x000f1;&#x000e9;-Pou</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="af1-pharmaceutics-13-00387">1</xref><xref ref-type="aff" rid="af2-pharmaceutics-13-00387">2</xref></contrib><contrib contrib-type="author"><name><surname>Mercad&#x000e9;-Frutos</surname><given-names>D&#x000e8;bora</given-names></name><xref ref-type="aff" rid="af1-pharmaceutics-13-00387">1</xref></contrib><contrib contrib-type="author"><name><surname>Su&#x000f1;&#x000e9;-Negre</surname><given-names>Josep Mar&#x000ed;a</given-names></name><xref ref-type="aff" rid="af1-pharmaceutics-13-00387">1</xref><xref ref-type="aff" rid="af2-pharmaceutics-13-00387">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6899-066X</contrib-id><name><surname>P&#x000e9;rez-Lozano</surname><given-names>Pilar</given-names></name><xref ref-type="aff" rid="af1-pharmaceutics-13-00387">1</xref><xref ref-type="aff" rid="af2-pharmaceutics-13-00387">2</xref><xref ref-type="author-notes" rid="fn1-pharmaceutics-13-00387">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1576-5586</contrib-id><name><surname>Garc&#x000ed;a-Montoya</surname><given-names>Encarna</given-names></name><xref ref-type="aff" rid="af1-pharmaceutics-13-00387">1</xref><xref ref-type="aff" rid="af2-pharmaceutics-13-00387">2</xref><xref ref-type="author-notes" rid="fn1-pharmaceutics-13-00387">&#x02020;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Fari&#x000f1;a</surname><given-names>Jos&#x000e9; B.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-13-00387"><label>1</label>Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain; <email>khadirouaz@gmail.com</email> (K.R.); <email>annanardi@ub.edu</email> (A.N.-R.); <email>msunepou@gmail.com</email> (M.S.-P.); <email>debora.mercade@ub.edu</email> (D.M.-F.); <email>jmsune@ub.edu</email> (J.M.S.-N.); <email>perezlo@ub.edu</email> (P.P.-L.); <email>encarnagarcia@ub.edu</email> (E.G.-M.)</aff><aff id="af2-pharmaceutics-13-00387"><label>2</label>Pharmacotherapy, Pharmacogenetics and Pharmaceutical Technology Research Group Bellvitge Biomedical Research Institute (IDIBELL), Av. Gran via de l&#x02019;Hospitalet, 199-203, 08090 Barcelona, Spain</aff><author-notes><corresp id="c1-pharmaceutics-13-00387"><label>*</label>Correspondence: <email>blchiclr8@alumnes.ub.edu</email>; Tel.: +34-638-53-53-42</corresp><fn id="fn1-pharmaceutics-13-00387"><label>&#x02020;</label><p>These authors contribute equally to this paper.</p></fn></author-notes><pub-date pub-type="epub"><day>13</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2021</year></pub-date><volume>13</volume><issue>3</issue><elocation-id>387</elocation-id><history><date date-type="received"><day>18</day><month>2</month><year>2021</year></date><date date-type="accepted"><day>10</day><month>3</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="pmc" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>This theoretical study seeks to critically review the use of excipients in the paediatric population. This study is based on the rules and recommendations of European and American drug regulatory agencies. On the one hand, this review describes the most frequent excipients used in paediatric medicine formulations, identifying the compounds that scientific literature has marked as potentially harmful regarding the side effects generated after exposure. On the other hand, this review also highlights the importance of carrying out safety -checks on the excipients, which, in most cases, are linked to toxicity studies. An excipient in the compilation of paediatric population databases is expected to target safety and toxicity, as in the STEP database. Finally, a promising pharmaceutical form for child population, ODT (Orally Disintegrating Tablets), will be studied.</p></abstract><kwd-group><kwd>excipients</kwd><kwd>paediatrics</kwd><kwd>security</kwd><kwd>toxicology</kwd><kwd>STEP and ODT</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-13-00387"><title>1. Introduction</title><p>The scientific literature suggests that most commercialized drugs are not suitable to be used on the paediatric population, as they are presented in an inappropriate pharmaceutical dosage or form, or because of the excipients they contain. In the face of this reality, compounding is the alternative for paediatric patients. Auxiliary substances or excipients should be used in the development of a compounding formula in order to allow the drug to be administered in an easily and personalized manner. By doing so, the active ingredient will be formulated in a stable, effective, and safe form [<xref rid="B1-pharmaceutics-13-00387" ref-type="bibr">1</xref>].</p><p>The process of formulating excipients in paediatrics is a complicated task that requires various considerations to be accounted for in order to for them to be appropriate; variables such as an acceptable taste, age, dosage forms, among others, must be taken into account when selecting safe excipients. Furthermore, children&#x02019;s rapid growth and development are associated with changes in various organs, body composition, protein bonds, active transport mechanisms and metabolic pathways, which must also be taken into account [<xref rid="B2-pharmaceutics-13-00387" ref-type="bibr">2</xref>]. In addition to being a complicated task, it is also a critical step in the development of paediatric formulations, as some acceptable excipients in formulations for adult patients are not suitable for paediatric use.</p><p>It is thus of particular relevance to carry out an assessment of the safety of excipients prior to their use in paediatrics. Indeed, Georg Schmitt [<xref rid="B3-pharmaceutics-13-00387" ref-type="bibr">3</xref>] advocates for non-clinical safety studies being carried out in juvenile animals to assess excipient toxicity or sensibility and also to establish safe exposures in paediatric age groups. He specifically recommends that excipient toxicity studies also be carried out, as they provide a detailed assessment of clinical risk. He further suggests that even excipients with significant toxic potential for children may be acceptable after a rigorous assessment of the risk they pose is made. Another factor to be considered for toxicological studies is the extent to which the target disease may be alleviated by the formulation of that medicine. Thus, pharmaceutical companies should filter the demands for safety assessments by selecting those that will contribute to a potential therapeutic benefit, while helping to develop a reference list of excipients generally considered safe for use in paediatric formulations. In this way, the clinical decision-making process will be made easier.</p><p>This theoretical study&#x02019;s main objective is to critically review the use of excipients in paediatrics with an emphasis on the issue of safety, mainly on the basis of toxicological studies. This will enable information to be obtained that will allow decisions to be made regarding the masterful preparation of formulations. This study also seeks to investigate the development of databases and initiatives in order to record corroborated information on excipients for paediatric use, thus serving as a guide for clinical professionals. </p><p>To do this, databases such as Web of Science, PubMed, SciFinder and SciFindern Search, as well as books related to the subject, were consulted. Please note that most of the selected literature is from the last two decades. Subsequently, six tables were created to provide details on the data obtained:
<list list-type="bullet"><list-item><p><xref rid="pharmaceutics-13-00387-t001" ref-type="table">Table 1</xref>. Toxicity database.</p></list-item><list-item><p><xref rid="pharmaceutics-13-00387-t0A1" ref-type="table">Table A1</xref>. Most important characteristics of the excipients discussed in this review (in alphabetical order).</p></list-item><list-item><p><xref rid="pharmaceutics-13-00387-t0A2" ref-type="table">Table A2</xref>. Examples of solid and semi-solid medicines used in Spain for the paediatric population: List of excipients and relevant characteristics of the pharmaceutical form (PF) (performed consultation of CIMA database, September 2020).</p></list-item><list-item><p><xref rid="pharmaceutics-13-00387-t0A3" ref-type="table">Table A3</xref>. Examples of liquid medicines used in paediatrics: List of excipients and relevant characteristics of (PF).</p></list-item><list-item><p><xref rid="pharmaceutics-13-00387-t0A4" ref-type="table">Table A4</xref>. Examples of FDA-registered drugs used in paediatrics (FDA database and DAILYMED October 2020).</p></list-item><list-item><p><xref rid="pharmaceutics-13-00387-t0A5" ref-type="table">Table A5</xref>. Examples of liquid formulations for paediatric use in research articles.</p></list-item></list></p></sec><sec id="sec2-pharmaceutics-13-00387"><title>2. Paediatric Regulatory Context</title><p>Changes in physical, metabolic and psychological processes that occur during children&#x02019;s growth, from birth to adulthood, suggest that children should not be considered as young adults, and nor should they be grouped as a single group. Rather, the pharmaceutical development of paediatric drugs should focus on several acceptable dosage forms that are able to meet the needs of most children in different age groups. This can be achieved by developing dosage forms which facilitate the administration of a dose range which would vary according to the child&#x02019;s age and/or other important parameters [<xref rid="B4-pharmaceutics-13-00387" ref-type="bibr">4</xref>]. </p><p>Before there were regulations for the development of paediatric drugs, children were known as &#x0201c;therapeutic orphans&#x0201d;. They lost the advances of conventional medicine, since the vast majority of advances were aimed at the adult population, and there were not many approved medicines for children. Children were treated with approved drugs following successful studies on adults, but with few or no trials on the paediatric population (off-label use). The large number of subsequent issues with clinical trials on children, as well as the need for drug authorization in the paediatric population, among other reasons, were the driving factors for the creation of a legislative and regulatory framework for clinical studies in paediatrics. The US pioneered these in the late 1980s, and with the adoption of these paediatric regulatory initiatives, significant improvements were made [<xref rid="B4-pharmaceutics-13-00387" ref-type="bibr">4</xref>].</p><p>It was only in 1997 that European regulators agreed to strengthen legislation on the use of new medicines in children. In 2000, European health ministers asked the European Commission to make proposals for a legislation to ensure that new paediatric medicines placed on the market were tailored to the specific needs of children. In 2004, after a major debate, a regulatory bill was issued, which took into account lessons learned from paediatric regulation that the US was already addressing [<xref rid="B5-pharmaceutics-13-00387" ref-type="bibr">5</xref>]. On 26 January 2007, the Paediatric Regulation entered into force in the European Union, and focused mainly on regulating the development of paediatric formulations for children between 0 and 18 years of age, but also sought to:
<list list-type="bullet"><list-item><p>Ensure that these medicines were of good quality. </p></list-item><list-item><p>Verify that paediatric medicines were produced following ethical and legitimate research, that children were not subjected to unnecessary trials. </p></list-item><list-item><p>Improve the accessibility and availability of information on drug use in the paediatric population. </p></list-item><list-item><p>Such regulations led to the establishment of the Paediatric Committee (PDCO), whose main function was to regulate the studies that companies should conduct in children as part of a Paediatric Research Plan (PRP) [<xref rid="B6-pharmaceutics-13-00387" ref-type="bibr">6</xref>].</p></list-item><list-item><p>The Paediatric Regulation consists of [<xref rid="B7-pharmaceutics-13-00387" ref-type="bibr">7</xref>]:</p></list-item><list-item><p>Regulation (EC) 1901/2006 of the European Parliament and of the Council on medicinal products for paediatric use; and</p></list-item><list-item><p>Regulation (EC) 1902/2006, an amending regulation in which changes were made to the original text in relation to the European Commission&#x02019;s decision-making procedures.</p></list-item></list></p><p>In October 2017, the European Commission published a ten-year report on the implementation of the Paediatric Regulation. The report showed an increase in medicines for children in most therapeutic areas over the past ten years, especially in rheumatology and infectious diseases. However, in rare diseases, progression was lower. A report on the first five years was also published in June 2013, which concluded that paediatric development had become a more integral part of the overall development of medicines in the European Union [<xref rid="B4-pharmaceutics-13-00387" ref-type="bibr">4</xref>,<xref rid="B8-pharmaceutics-13-00387" ref-type="bibr">8</xref>].</p><p>The European Guideline on pharmaceutical development of medicines for paediatric used [<xref rid="B4-pharmaceutics-13-00387" ref-type="bibr">4</xref>] offers several tips for paediatric drug formulation.</p><p>Excipients in a paediatric formulation should be chosen appropriately, avoiding any excipients that are potentially toxic or unsuitable for children. Choosing the right excipients in the development of a new paediatric drug is one of the most important aspects, as it requires special safety considerations. In general, the following aspects should be taken into account when selecting an appropriate excipient for a paediatric medicinal product [<xref rid="B4-pharmaceutics-13-00387" ref-type="bibr">4</xref>]:
<list list-type="bullet"><list-item><p>Excipient function in formulation and possible alternatives.</p></list-item><list-item><p>Safety profile of the excipient for children in target age groups, based on a unique and daily exposure.</p></list-item><list-item><p>Expected duration of treatment: short term (a single dose for a few days) or long term (weeks and/or months).</p></list-item><list-item><p>Severity of the condition to be treated and therapeutic alternatives.</p></list-item><list-item><p>Patient acceptability, including palatability.</p></list-item><list-item><p>Allergies and sensitization. Children suffer from sensitization problems more commonly than adults. Applicants should avoid, when possible, excipients with known potential to cause sensitization or allergies.</p></list-item></list></p><p>If the use of any excipient in the formulation that produces or may pose any risk to the child cannot be avoided, the added value of the chosen pharmaceutical form of dosing (and the route of administration) should be balanced with the possible use of another. However, security issues can only become apparent when the product is used on a larger scale.</p><p>Furthermore, the first joint paediatric regulatory action was taken by the ICH (The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use), an organization working on harmonizing drug regulation requirements between the EU, Japan and the US. In July 2000 Guideline E11 (R1) was published: Clinical investigation of medicinal products in the paediatric population, with the final version in August 2017 [<xref rid="B9-pharmaceutics-13-00387" ref-type="bibr">9</xref>].</p><p>The objectives of this guide were to encourage and facilitate the development of paediatric medicines at the international level, as well as to provide a summary of critical problems in the development of these medicines and new approaches to their safe, efficient and ethical clinical study. ICH E11 became an important tool in the design of paediatric clinical research worldwide, providing guidelines (rather than proscribing practice) [<xref rid="B9-pharmaceutics-13-00387" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceutics-13-00387" ref-type="bibr">10</xref>].</p><p>The WHO launched the initiative Making Medicines Child Size in 2008 to issue a list of essential medicines for children, betting on quality paediatric development and adequate access of these medicines to the entire paediatric population, in particular underdeveloped countries [<xref rid="B11-pharmaceutics-13-00387" ref-type="bibr">11</xref>]. The most current one is the 7th edition, which was published in 2019 (WHO model list of essential medicines for children) [<xref rid="B12-pharmaceutics-13-00387" ref-type="bibr">12</xref>].</p><p>In the early 1980s, the FDA (Food and Drug Administration) began taking steps to provide incentives to the pharmaceutical industry for the development of paediatric drugs. In 1994, the Paediatric Labelling Rule was issued, requiring the authorization of a new paediatric drug to be supported by safety and efficacy data to support its use. However, that rule was not mandatory and was unsuccessful. For this reason, the US-FDA proposed in 1998 Paediatric rule which proposed to guarantee the above-mentioned objectives, both at and after the approval of the new drug [<xref rid="B13-pharmaceutics-13-00387" ref-type="bibr">13</xref>].</p><p>It should also be noted that the FDA (Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients) published a document that provides guidance on the development of safety profiles to support the use of new excipients as components of drugs or biological products, which could be applied in paediatric experiments [<xref rid="B14-pharmaceutics-13-00387" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-13-00387" ref-type="bibr">15</xref>].</p><sec><title>Examples of Databases and Initiatives for the Registration of Information on Excipients Used in the Paediatric Population</title><p>It is certainly necessary to take into account the safety of excipients used in paediatric products, as the toxicity of these excipients may differ from that of adults [<xref rid="B16-pharmaceutics-13-00387" ref-type="bibr">16</xref>]. Under this assumption, it is essential to develop methodologies that provide an integrated assessment of exposure to potentially toxic excipients contained in medicines. Therefore, in 2007, members of pharmaceutical industries, hospitals and academics interested in improving drug formulations in paediatrics founded the European Paediatric Formulation Initiative (EUPFI). The latter sought to address safety problems linked to excipients used in children [<xref rid="B17-pharmaceutics-13-00387" ref-type="bibr">17</xref>], as well as the development of platforms for the systematic evaluation of excipients in new-borns [<xref rid="B18-pharmaceutics-13-00387" ref-type="bibr">18</xref>].</p><p>EuPFI is currently a consortium of 10 pharmaceutical companies, 5 universities, 1 hospital and, exclusively, the European Medicines Agency (EMA) as an observer. The goals and objectives of this consortium are summarized in [<xref rid="B19-pharmaceutics-13-00387" ref-type="bibr">19</xref>]:<list list-type="order"><list-item><p>Identify the problems and challenges associated with the development of paediatric formulation and consider ways to obtain better medicines and dosage forms clinically relevant to children.</p></list-item><list-item><p>Promote early pharmaceutical consideration for the development of paediatric medicines. </p></list-item><list-item><p>Identify potential information and knowledge gaps in the development of paediatric formulations.</p></list-item><list-item><p>Improve the availability of information from paediatric formulations.</p></list-item></list></p><p>The scientific literature shows that excipients commonly used in adult medicines have been associated with high toxicological risks and safety problems in children [<xref rid="B20-pharmaceutics-13-00387" ref-type="bibr">20</xref>]. Following the United States Paediatric Formulation Initiative (USPFI) and Global Paediatric Research (GRIP), the Paediatric Excipient Safety and Toxicity Database (STEP) was created to address the need for effortless access to information about the excipients&#x02019; safety and toxicity [<xref rid="B21-pharmaceutics-13-00387" ref-type="bibr">21</xref>]. The STEP database is presented as a resource of information to facilitate access to data on the use and acceptability of excipients in children, thus allowing a rapid evaluation of the risks due to the use of certain excipients in the paediatric population and an improvement in the scientific decision making [<xref rid="B2-pharmaceutics-13-00387" ref-type="bibr">2</xref>,<xref rid="B22-pharmaceutics-13-00387" ref-type="bibr">22</xref>]. Furthermore, the STEP database provides comprehensive and comparative information on the safe use and acceptability of excipients in paediatrics. For the reasons listed above, the STEP database stands out with respect to other existing public resources (such as TOXNET) or databases (such as Vitic or ACToR) that organize their informational content in free text format, thus preventing data from being filtered as needed (see <xref rid="pharmaceutics-13-00387-t001" ref-type="table">Table 1</xref>) [<xref rid="B23-pharmaceutics-13-00387" ref-type="bibr">23</xref>].</p><p>In general, the above purposes go in line with increasing the number of excipients registered in the database to be useful in practical research. Therefore, the following selection criteria were considered for excipients of interest [<xref rid="B2-pharmaceutics-13-00387" ref-type="bibr">2</xref>]:<list list-type="order"><list-item><p>Excipients known to be toxic/have general safety issues.</p></list-item><list-item><p>Frequency of appearance as contaminants or toxics in paediatrics (where applicable).</p></list-item><list-item><p>Evidence in the toxicity literature in paediatrics. The above criteria were applied to identify excipients for inclusion in the STEP database. Excipients were shortlisted/prioritized through surveys within EU and US PFI members.</p></list-item></list></p><p>According to the above criteria, in the development of databases on the safety and toxicity of excipients in the paediatric population, the following are prioritized, as they are most likely to cause damage and side effects in this population [<xref rid="B2-pharmaceutics-13-00387" ref-type="bibr">2</xref>]:<list list-type="order"><list-item><p>Propylene glycol (PG) </p></list-item><list-item><p>Ethanol </p></list-item><list-item><p>Polysorbate 80</p></list-item><list-item><p>Benzyl alcohol</p></list-item><list-item><p>Parabens (propyl, methyl, ethyl and butyl)</p></list-item><list-item><p>Benzalkonium chloride </p></list-item><list-item><p>Aspartame</p></list-item><list-item><p>Sorbitol</p></list-item><list-item><p>Benzoic acid</p></list-item><list-item><p>Sodium benzoate</p></list-item></list></p><p>In 2014, the first version of the STEP database was launched for the systematic evaluation of its integrity, quality, configurability, usability, and maintainability under the daily practices of the different and diverse professionals who use it. After launch, a validation study of the tool was initiated with the following objectives [<xref rid="B2-pharmaceutics-13-00387" ref-type="bibr">2</xref>]:
<list list-type="order"><list-item><p>Validate the STEP Version 1 database against the potential needs of end users to ensure that the STEP database meets users&#x02019; expectations.</p></list-item><list-item><p>Evaluate the functionality and usability of data application by
<list list-type="alpha-lower"><list-item><p>Ensuring proper ease of use (navigation), understanding and user satisfaction.</p></list-item><list-item><p>Characterizing how easy it is to perform a task using the database.</p></list-item><list-item><p>Identifying problems in interaction with systems.</p></list-item></list>
</p></list-item><list-item><p>Evaluate the impact of this database on the development of paediatric medicines.</p></list-item><list-item><p>Establish viable recommendations to further improve the functionality of the system and increase its beneficial effects on the development of paediatric medicines.</p></list-item></list></p><p>The results of the validation study identified different database usage issues, which are grouped into three areas: I. Content and presentation of results; II. Adequacy of the database to the characteristics of different users, navigation features; and III. Search. Many of the problems observed might have happened due to assuming that users would have sufficient knowledge, therefore some elements were not clearly exposed for the new user to understand. Furthermore, users with limited computer skills may also find the registration process confusing. These issues involved changes and improvements to STEP design and functionality, making it a more efficient database when deriving from a Version 2 [<xref rid="B21-pharmaceutics-13-00387" ref-type="bibr">21</xref>].</p><p>To perform an adequate risk/benefit assessment of the current medication standard, it is necessary to compare the daily amount of excipients in the most vulnerable patient with clinically established safety levels for the same age group. The SEEN project is an example of this, as it developed a retrospective cohort study, with neonatal patients (age 5 or younger) treated with multiple medicines. Preparations were recorded with ethanol, propylene glycol, benzyl alcohol, parabens, aspartame, glycerol, sorbitol and polysorbate-80 and cumulative amounts [<xref rid="B24-pharmaceutics-13-00387" ref-type="bibr">24</xref>] were calculated.</p><p>The results obtained demonstrated limited knowledge about the acceptability of different dosage forms, flavours and, more importantly, the safety of formulation excipients in relation to the age and stage of development of children [<xref rid="B24-pharmaceutics-13-00387" ref-type="bibr">24</xref>].</p></sec></sec><sec id="sec3-pharmaceutics-13-00387"><title>3. Excipients: Functions and Main Adverse Effects </title><p>Paediatric formulations need excipients to maintain their quality and promote the acceptability of childhood patients [<xref rid="B25-pharmaceutics-13-00387" ref-type="bibr">25</xref>]. However, just because they are necessary does not mean that they are toxicity-free products; in fact, a study by Georgi and collaborators [<xref rid="B26-pharmaceutics-13-00387" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-13-00387" ref-type="bibr">27</xref>] confirms that many of the medicines used in paediatrics contain some toxic or potentially toxic excipient for the paediatric population, with this data being present in two-thirds of new-borns in 21 European countries. Thus, excipients used in paediatric formulations require a thorough assessment of short-term and long-term safety prior to their use in these formulations [<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>]. A classification of the main excipients will then be developed according to the role they play in the formulation, mentioning the possible adverse effects on the paediatric population. Furthermore, a summary appendix (<xref ref-type="app" rid="app2-pharmaceutics-13-00387">Appendix B</xref> (<xref rid="pharmaceutics-13-00387-t0A1" ref-type="table">Table A1</xref>)) of the excipients discussed in this paper will be prepared.</p><sec id="sec3dot1-pharmaceutics-13-00387"><title>3.1. Diluents </title><p>Lactose, starch and microcrystalline cellulose are often used as diluents, as they are generally safe in the adult population. </p><sec id="sec3dot1dot1-pharmaceutics-13-00387"><title>3.1.1. Lactose </title><p>Lactose, which is a mandatory excipient, is recommended not to be used in patients with lactose intolerance and is contraindicated in patients with galactosemia [<xref rid="B1-pharmaceutics-13-00387" ref-type="bibr">1</xref>]. It may cause hypersensitivity reactions in children and new-borns. Infants with lactose intolerance do not properly metabolize lactose, due to the deficiency of the enzyme lactase, thus causing the accumulation of lactic acid, hydrogen and carbon dioxide. Symptoms such as severe abdominal pain, flatulence, bloating or swelling and diarrhoea may, therefore, appear, as well as systemic symptoms such as muscle, joint pain and eczema [<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>]. It should be noted that children may sometimes have very severe and prolonged reactions to lactose that can lead to additional complications, such as dehydration, bacterial proliferation and metabolic acidosis [<xref rid="B1-pharmaceutics-13-00387" ref-type="bibr">1</xref>,<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>].</p><p>Starch, dehydrated calcium hydrogen phosphate, erythritol and cellulose powder are alternatives to lactose in paediatric formulations. They have lactose-like flow properties and produce tablets that can disaggregate in a time less than lactose [<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>].</p></sec><sec id="sec3dot1dot2-pharmaceutics-13-00387"><title>3.1.2. Starch</title><p>Starch is one of the most commonly used excipients and, in addition to being a diluent, it has binder and disintegrating properties. Due to its properties, starch should be preserved in a dry environment, as it can be an excellent growing medium for microorganisms in case of moisture, which may cause microbiological contaminations. In addition, it may give proliferation of carcinogenic aflatoxins, if contaminated by two species of fungi closely enhanced by each other: Aspergillus flavus and Aspergillus parasiticus [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]. </p></sec><sec id="sec3dot1dot3-pharmaceutics-13-00387"><title>3.1.3. Microcrystalline Cellulose</title><p>Microcrystalline cellulose is a partially depolymerized purified cellulose that is presented as a white, odourless and tasteless crystalline powder composed of porous particles. It is commercially available in different particle sizes and moisture grades that have different properties and applications. It is considered a relatively non-toxic and non-irritating material. It is not absorbed systemically after oral administration and therefore has little toxic potential [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-13-00387" ref-type="bibr">30</xref>].</p><p>Microcrystalline cellulose is used in pharmaceutical products, mainly as a binder and thinner in tablet and oral capsule formulations. In addition to its use as a binder and thinner, it also has some lubricating and disintegrating properties that make it useful for forming tablets [<xref rid="B30-pharmaceutics-13-00387" ref-type="bibr">30</xref>].</p></sec></sec><sec id="sec3dot2-pharmaceutics-13-00387"><title>3.2. Solvents </title><p>Some of the most common solvents are water, ethyl alcohol, propylene glycol (PG), glycerol and polyethylene glycol [<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>].</p><sec id="sec3dot2dot1-pharmaceutics-13-00387"><title>3.2.1. Water</title><p>Water is the most commonly used agent in paediatric formulations, as liquid preparations are easier to administrate and allow a more accurate dose adjustment [<xref rid="B1-pharmaceutics-13-00387" ref-type="bibr">1</xref>,<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]. Water is an ideal medium for the proliferation of microorganisms (bacteria and fungi) despite their purification, which is why antimicrobial agents have to be added.</p><p>In paediatric oral formulations, the total volume of fluid is of vital importance for the taste and ability to adequately measure the volume to be administered: in children under 5 years of age a volume of less than 5 mL should be administered and, in children under 10 years of age, a volume of less than 10 mL [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>] should be administered.</p></sec><sec id="sec3dot2dot2-pharmaceutics-13-00387"><title>3.2.2. Ethyl Alcohol (Ethanol)</title><p>Ethanol is one of the excipients of concern to international health regulatory agencies, as it causes neurotoxicity and cardiovascular problems in the paediatric population; it is a potentially harmful excipient in neonates. For this reason, permissible maximum limits have been set and, in some countries, non-alcoholic medicines are to be established. It is a very permeable excipient with regard to the blood&#x02013;brain barrier, and the one most commonly used in oral medicinal products, reaching 63% of cases [<xref rid="B26-pharmaceutics-13-00387" ref-type="bibr">26</xref>]. It is rapidly absorbed into the gastrointestinal tract and is primarily metabolized in the liver to acetaldehyde, which is oxidized to acetate [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>].</p><p>Indeed, Macrel and Bernando&#x02019;s review of liquid formulations in Brazil has furthered our understanding of the high use of ethanol. These researchers demonstrated that ethanol is used in various concentrations and functions: as solvent (main function), co-saver, flavouring agent, preservative and as an extraction solvent in herbal medicines [<xref rid="B26-pharmaceutics-13-00387" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-13-00387" ref-type="bibr">27</xref>]. It also has antimicrobial properties and increases the permeability of many preparations [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>].</p><p>The use of ethanol as an excipient carries potential hazards and adverse effects, which are already observed at a dose of 100 mg/dL. These effects include hypoglycaemia, acidosis and hydro-electrolytic alterations. Very high intake can lead to stupor, coma, respiratory depression and cardiovascular collapse. Hypoglycaemic seizures may also occur in children [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B31-pharmaceutics-13-00387" ref-type="bibr">31</xref>]. For all these side effects, any alcohol should be avoided in paediatric forms. However, it is still used in many liquid preparations, because it is the only solvent that allows the solubilization of certain active substances [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>].</p><p>In both the United States and the European Union, guidance on maximum ethanol limits in medicinal formulations is increasing [<xref rid="B17-pharmaceutics-13-00387" ref-type="bibr">17</xref>]. According to the World Health Organization and a regulation existing in the United States, the maximum alcohol content in paediatric formulations should not exceed the limits specified in <xref rid="pharmaceutics-13-00387-t0A1" ref-type="table">Table A1</xref> [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B31-pharmaceutics-13-00387" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-13-00387" ref-type="bibr">32</xref>].</p><p>It should be noted that ethanol was also able to interact with many active substances of other medicines that the child is taking [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>] and, therefore, possible interactions must be studied prior to concomitant administration. Furthermore, new contributions in the scientific literature on excipients, including ethanol, is expected to help health professionals predict the risks of using a particular excipient, especially in the paediatric population. For example, the guideline excipients in the label and package leaflet of medicinal products for human use alerts on the risk of the use of ethanol and proposes changes on its use.</p></sec><sec id="sec3dot2dot3-pharmaceutics-13-00387"><title>3.2.3. Propylene Glycol (PG)</title><p>PG is used as a solvent to stabilize substances that are not water soluble, in parenteral and non-parenteral formulations. It also has moisturizing, antimicrobial properties and can be used as plasticizer. It is rapidly absorbed through the gastrointestinal tract and damaged skin and metabolized in the liver to lactic acid and pyruvic acid [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>].</p><p>Exposure to high doses of PG may affect the Central Nervous System, especially in new-borns and children under 4 years of age [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]. Due to children&#x02019;s physiological and metabolic immaturity, PG can accumulate rapidly causing toxicity [<xref rid="B33-pharmaceutics-13-00387" ref-type="bibr">33</xref>]. In new-borns, its half-life is very long, almost seventeen hours, compared to that of adults, which is about five hours [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]. The GRAS (Generally Recognized as Safe) classification of excipients typically does not consider the differences in physiological and metabolic maturation between the paediatric and adult populations [<xref rid="B33-pharmaceutics-13-00387" ref-type="bibr">33</xref>], a fact that justifies some important adverse reactions presented by PG in the paediatric population [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]:<list list-type="bullet"><list-item><p>Hyperosmolar syndrome in burnt children with topical arsenic sulfadiazine ointment containing PG.</p></list-item><list-item><p>Precipitation of irreversible deafness in pretermits who received a multivitamin complex containing PG.</p></list-item><list-item><p>Parenterally it is possible to observe haemolysis, seizures, respiratory depression, hypertension.</p></list-item><list-item><p>Contact dermatitis is topically observed.</p></list-item></list></p><p>In the 1980s, cases of biochemical abnormalities, including hyperosmolarity, lactic acidosis and elevated levels of creatinine and bilirubin, were documented after exposure to 3 g/day of PG and for at least 5 consecutive days. Clinical symptoms, including seizures and bradycardia episodes [<xref rid="B33-pharmaceutics-13-00387" ref-type="bibr">33</xref>], then appeared. In 2011, the U.S. FDA reported health problems in premature new-borns associated with the use of Kaletra<sup>&#x000ae;</sup> (lopinavir/ritonavir) solution; liquid preparation containing high amounts of PG and ethanol [<xref rid="B33-pharmaceutics-13-00387" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-13-00387" ref-type="bibr">34</xref>].</p><p>Exposure to PG in new-borns and children under 4 years of age remains common, despite historical and contemporary reports dealing with toxic adverse effects of this excipient. Thus, the study of Allegaert J. [<xref rid="B33-pharmaceutics-13-00387" ref-type="bibr">33</xref>] in terms of the PG research project in new-borns is of great interest, as it provides scientific evidence on the tolerance and plasma clearance of this excipient, including differences in elimination pathways (renal pathway compared to the hepatic pathway).</p></sec><sec id="sec3dot2dot4-pharmaceutics-13-00387"><title>3.2.4. Glycerol </title><p>Glycerol, a mandatory excipient (E-422), is used as solvent, sweetener, viscosizer and preservative.</p><p>When used at high concentrations (more than 40%), it can cause mucositis in the stomach, as well as diarrhoea and electrolyte disturbances due to its hygroscopic and osmotic properties. Therefore, a maximum amount of 10 g/dose [<xref rid="B1-pharmaceutics-13-00387" ref-type="bibr">1</xref>,<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>] has been established.</p><p>In the adult population glycerol has few adverse effects. However, cases of neurological toxicity have been reported in the paediatric population [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>].</p></sec><sec id="sec3dot2dot5-pharmaceutics-13-00387"><title>3.2.5. Polyethylene Glycol (PEG)</title><p>PEG is a polar and water-soluble substance used as a co-solvent, suspensor and viscosity agent. The PEG 400 is the most used in liquid formulations. It may cause some laxative effect when taken orally, with the maximum daily dose established in adults at 10 mg/kg/day [<xref rid="B1-pharmaceutics-13-00387" ref-type="bibr">1</xref>]. </p><p>PEG has low oral bioavailability and renal elimination. Due to its properties, significant adverse effects such as diarrhoea and nephrotoxicity have been reported, so the maximum recommended daily dose is 10 mg/kg body weight [<xref rid="B1-pharmaceutics-13-00387" ref-type="bibr">1</xref>]. It can also cause some laxative effect when taken orally. When new-borns and infants are exposed to high doses of PEG, gastrointestinal disorders, adverse effects typical of alcoholic solvents may occur [<xref rid="B1-pharmaceutics-13-00387" ref-type="bibr">1</xref>,<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>]. </p></sec></sec><sec id="sec3dot3-pharmaceutics-13-00387"><title>3.3. Coating Agents</title><sec><title>Phthalates</title><p>Phthalates play a primary role as a coating agent (film-forming, plasticizer) in medicinal formulations.</p><p>Exposure of pregnant women to phthalates has been associated with abnormalities in the development of the foetus, such as cleft palate and skeletal malformations; abnormalities that can end in stillbirth. It was observed that they have a high potential to produce toxicity in the development of experimental animals, as well as in their reproduction [<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>].</p><p>Due to these risks of certain phthalates to health, in March 2012, the CDER published a guide to orient the pharmaceutical industry on the use of phthalates: &#x0201c;Limiting the use of certain phthalates as excipients in CDER regulated products&#x0201d;. This guidance document recommends limiting the use of certain phthalates, such as dibutyl phthalate (DBP) and di(2-ethylhexyl) phthalate (DEHP) [<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>].</p></sec></sec><sec id="sec3dot4-pharmaceutics-13-00387"><title>3.4. Preservatives</title><p>Preservatives are a group of excipients that prevent microbial growth and, consequently, the degradation of the active substance and the possible alteration of the organoleptic characteristics of the final formula [<xref rid="B35-pharmaceutics-13-00387" ref-type="bibr">35</xref>].</p><p>The American Academy of Paediatrics does not recommend the use of preservatives in reparations for patients under 3 years of age due to the lack of physiological and metabolic maturation of these patients. This lack of maturation may lead to the accumulation of preservatives in the liver, a fact that increases the risk of cardiovascular collapse, in addition to producing non-specific reactions or even allergies [<xref rid="B1-pharmaceutics-13-00387" ref-type="bibr">1</xref>,<xref rid="B35-pharmaceutics-13-00387" ref-type="bibr">35</xref>]. It should be noted that preservatives are not contraindicated in children under 3 years of age, but should only be used in imperative cases [<xref rid="B1-pharmaceutics-13-00387" ref-type="bibr">1</xref>].</p><sec id="sec3dot4dot1-pharmaceutics-13-00387"><title>3.4.1. Sodium Benzoate </title><p>Sodium benzoate is a preservative widely used in pharmaceutical and cosmetic formulations, at concentrations between 0.02% and 0.05% [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]. Its maximum activity occurs in weakly acidic pH 4.5 solutions and is inactive at pH values greater than 5 [<xref rid="B35-pharmaceutics-13-00387" ref-type="bibr">35</xref>].</p><p>As side effects, it can cause contact hives and other allergies. In premature children, its use is contraindicated, as it presents a risk of metabolic acidosis and jaundice [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B35-pharmaceutics-13-00387" ref-type="bibr">35</xref>].</p><p>One of the large prospective studies conducted by Nellis and collaborators [<xref rid="B36-pharmaceutics-13-00387" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-13-00387" ref-type="bibr">37</xref>] in hospitalized neonates in Europe described the administration of eight potentially harmful excipients of interest (EOI) (parabens, polysorbate 80, propylene glycol, benzoates, sodium saccharine, sorbitol, ethanol and benzalkonium chloride) and identified risk factors resulting from exposure. Neonates appear to lack the ability to conjugate benzoates with glycine, leading to the accumulation of benzoic acid that can cause metabolic acidosis and neurotoxicity [<xref rid="B26-pharmaceutics-13-00387" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-13-00387" ref-type="bibr">27</xref>].</p><p>The ESNEE (European Study of Neonatal Exposure to Excipients) clinical study [<xref rid="B38-pharmaceutics-13-00387" ref-type="bibr">38</xref>] showed that sodium benzoate was found in 10 medicines given to new-borns, despite being a highly toxic excipient to them. Preservatives such as parabens (and their sodium salts) and propyl para-hydroxy-benzoate were also found in 24 paediatric medications, and ethanol in 8.</p></sec><sec id="sec3dot4dot2-pharmaceutics-13-00387"><title>3.4.2. Benzyl Alcohol </title><p>Benzyl alcohol presents antibacterial properties. For that reason, it is used as a preservative in a lot of medicines. Its activity depends on the pH; being at it is maximum at a low pH (between 2.5&#x02013;4.5). It is used at the concentration of 0.01&#x02013;0.15% in oral preparations [<xref rid="B35-pharmaceutics-13-00387" ref-type="bibr">35</xref>].</p><p>In adults, it is metabolized to benzoic acid, which is conjugated in the liver with glycine. As a result, the acid hippuric formed is excreted in urine. However, in new-borns, this conversion of the benzoic acid into hippuric acid is very diminished, because of the lack of liver maturation. That justifies fatal intoxication cases in new-borns who had their umbilical catheters cleaned with benzoic acid. Consequently, cases of metabolic acidosis and respiratory depression occurred. Additionally, other adverse effects have been described, like intraventricular bleeding, cerebral palsy and developmental delay. In some cases, there have been reactions of hypersensitivity, allergy and contact dermatitis [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B39-pharmaceutics-13-00387" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-13-00387" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-13-00387" ref-type="bibr">41</xref>].</p><p>In the 1990s, Svinning and collaborators [<xref rid="B42-pharmaceutics-13-00387" ref-type="bibr">42</xref>] conducted a review of the medical records of babies who weighed less than 1250 g at birth and were admitted to the neonatal intensive care unit. The main objective of this study was to assess the impact of the toxicity of benzyl alcohol, following discontinuation of the use of solutions to wash intravascular catheters containing benzyl alcohol. A significant decrease in mortality rate and incidence of Grade III/IV intraventricular haemorrhage was observed among infants weighing less than 1000 g at birth who were not exposed to benzyl alcohol (as opposed to those who were). </p><p>The maximum dose of benzoic acid (and other benzoates, calculated as benzoic acid) recommended by WHO is 5 mg/kg body weight per day in adults, a dose that, in children, logically, should be much lower [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B35-pharmaceutics-13-00387" ref-type="bibr">35</xref>]. As the effects on new-borns are severely toxic, the U.S. FDA has recommended the exclusion of benzyl alcohol from medications, intravenous fluids, and heparin washing solutions for them [<xref rid="B36-pharmaceutics-13-00387" ref-type="bibr">36</xref>]. The EMA states that any medicine containing benzyl alcohol &#x0201c;should not be given to premature babies and new-borns&#x0201d; [<xref rid="B42-pharmaceutics-13-00387" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-13-00387" ref-type="bibr">43</xref>]. In fact, currently, any exposure to benzyl alcohol is contraindicated in children under 3 years of age [<xref rid="B44-pharmaceutics-13-00387" ref-type="bibr">44</xref>].</p></sec><sec id="sec3dot4dot3-pharmaceutics-13-00387"><title>3.4.3. Benzalkonium Chloride</title><p>Benzalkonium chloride is a quaternary ammonium used in ophthalmic preparations at a concentration of 0.01&#x02013;0.02% (<italic>v/v</italic>). Generally, it is non-irritating or sensitizing and is well tolerated in skin solutions.</p><p>As a side effect, it can cause bronchoconstriction in asthmatic patients, if used in nebulization solutions. Furthermore, cases of ototoxicity may occur in otic preparations, hypersensitivity in topical skin preparations and respiratory failure in infants who ingest this excipient, with this side effect being the most severe [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>].</p></sec><sec id="sec3dot4dot4-pharmaceutics-13-00387"><title>3.4.4. Thiomersal</title><p>Thiomersal is a preservative widely used in vaccines and topical preparations, such as eye drops. Its toxicity is similar to mercury: in fact, it contains a mercury atom in its molecular structure. The concentration used depends on the medicinal product: in injectable preparations 0.01% is used and in ophthalmic solutions between 0.001% and 0.15% [<xref rid="B30-pharmaceutics-13-00387" ref-type="bibr">30</xref>]. </p><p>Several allergic hypersensitivity reactions (e.g., erythema, vesicles) have been reported. Therefore, health authorities have recommended their withdrawal from vaccines at risk of toxicity. Recently, thiomersal has also been implicated in the onset of autism spectrum disorders in children who received aluminium salt vaccines as an adjuvant. Accordingly, various countries (including Spain) no longer market paediatric vaccines with this component [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]. The use of single-dose vials is recommended in many cases to prevent the use of preservatives such as thiomersal or sulphites such as sodium metabisulphite [<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>].</p></sec><sec id="sec3dot4dot5-pharmaceutics-13-00387"><title>3.4.5. Parabens</title><p>Parabens are the most commonly used preservatives (also in cosmetics and foods), due to their wide antimicrobial spectrum and their effectiveness over a very wide pH range (between 4 and 8) [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B35-pharmaceutics-13-00387" ref-type="bibr">35</xref>]. </p><p>Parabens are of mandatory declaration. They are used at concentrations between 0.01 and 0.2% [<xref rid="B45-pharmaceutics-13-00387" ref-type="bibr">45</xref>], although it is most common to use a mixture in proportion 10:1 (0.2% methylparaben + 0.02% propylparaben). The maximum recommended daily dose is 10 mg/kg body weight [<xref rid="B35-pharmaceutics-13-00387" ref-type="bibr">35</xref>].</p><p>They may produce a cross-hypersensitivity reaction in patients allergic to aspirin. This is because the main metabolite of parabens is hydroxyparabenzoic acid, structurally very similar to aspirin [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>].</p><p>Recent pharmacovigilance studies have highlighted certain questions about the purported safety (non-teratogenic or carcinogenic) of parabens [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]. Alternatives should therefore be found, especially in paediatric formulations. Antimicrobials are not necessary for parenteral formulations. The absence of parabens and benzoates in 85% of parenteral prescriptions suggests that administration of these excipients can be largely avoided [<xref rid="B36-pharmaceutics-13-00387" ref-type="bibr">36</xref>]. </p></sec></sec><sec id="sec3dot5-pharmaceutics-13-00387"><title>3.5. Antioxidants </title><p>Antioxidants are a group of chemical compounds used to prevent oxidation of the active substances in formulations [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>].</p><sec id="sec3dot5dot1-pharmaceutics-13-00387"><title>3.5.1. Sulphites</title><p>Sulphites are antioxidants widely used in different formulations; sodium sulphite, sodium bisulfite, sodium metabisulphite and potassium metasulfite [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>] are the most common.</p><p>Regulatory agencies (e.g., FDA, EMA) consider excipient sulphites safe. However, they present risks and possible fatal side effects derived of their use. One of the most common cases occurs in asthmatic patients, who may develop severe bronchospasm if they take medicines containing sulphites in their formulation [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>].</p><p>The antioxidants constitute a group of compound chemists used to avoid the oxidation of the active principles in the formulations [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>].</p><p>It should be noted that a large number of people are sensitive to sulphites and may experience a variety of symptoms, including dermatological, gastrointestinal and respiratory symptoms. However, reactions that develop in the respiratory tract explain most cases of sensitivity to sulphites. It is important to note that several individuals experience a variety of symptoms after exposure to sulphites; therefore, skin, intestinal and respiratory reactions can occur simultaneously and in various combinations and severity. People with sensitive skin who regularly use cosmetics or topical medications containing sulphites have chronic skin symptoms, especially on the hands, perineum and face. Sensitivity to sulphites is a very real problem that significantly affects the health of many people, especially asthmatics. Sensitivity to sulphites should be considered when people show adverse reactions to a variety of exposures, without an obvious pattern, particularly when those people experience worsening asthma symptoms after consumption of foods such as dried fruits and wines, or adverse skin reactions, after the use of cosmetics or medicinal creams [<xref rid="B46-pharmaceutics-13-00387" ref-type="bibr">46</xref>].</p></sec><sec id="sec3dot5dot2-pharmaceutics-13-00387"><title>3.5.2. Propyl Gallate</title><p>Propyl gallate is an antioxidant used to prevent the breakdown of fatty acids. It is used at a concentration of 0.1% and also has a synergistic effect with other antioxidants. In neonates it can cause dermatitis, skin allergy and methemoglobinemia [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>].</p></sec></sec><sec id="sec3dot6-pharmaceutics-13-00387"><title>3.6. Sweeteners </title><p>The use of sweeteners varies between routes of administration and, like preservatives, are not necessary in parenteral administrations [<xref rid="B36-pharmaceutics-13-00387" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-13-00387" ref-type="bibr">37</xref>]. They have been linked to photosensitivity reactions, diarrhoea and poor absorption of nutrients [<xref rid="B36-pharmaceutics-13-00387" ref-type="bibr">36</xref>,<xref rid="B47-pharmaceutics-13-00387" ref-type="bibr">47</xref>].</p><p>The most commonly used sweeteners in pharmaceutical formulations are sucrose, sorbitol, mannitol, aspartame and sucralose.</p><sec id="sec3dot6dot1-pharmaceutics-13-00387"><title>3.6.1. Sucrose </title><p>Sucrose is a natural disaccharide that is hydrolysed in the gut into two monosaccharides: glucose and fructose.</p><p>In children with type I diabetes, the use of sucrose should be avoided. Very high concentrations (up to 35% are used for liquid formulations such as syrups). When the patient needs prolonged treatment with these preparations, he or she is at risk of dental damage. It has also been described that administration at very high doses on a daily basis may be carcinogenic [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>].</p></sec><sec id="sec3dot6dot2-pharmaceutics-13-00387"><title>3.6.2. Sorbitol </title><p>Sorbitol is a monosaccharide that is not absorbed into the digestive tract and is therefore considered safe in paediatric patients, although it is laxative at high doses. It is also used as a diluent as well as capsule plasticizer [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>].</p><p>Sorbitol is another example of an excipient that causes gastrointestinal disorders, such as abdominal pain, swelling, flatulence, vomiting and osmotic diarrhoea. Because sorbitol is metabolized to fructose, it should be avoided on children with fructose intolerance and hypoglycaemia. In isolated cases it can cause liver damage leading to coma and even death [<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-13-00387" ref-type="bibr">30</xref>].</p><p>In infants the accumulation of sorbitol can lead to diabetic complications such as retinopathy and cataracts. Therefore, the amount of sorbitol is limited to 0.3 mg/kg in paediatric formulations [<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>].</p></sec><sec id="sec3dot6dot3-pharmaceutics-13-00387"><title>3.6.3. Mannitol</title><p>Mannitol is used as a sweetener and as a diluent. It has been linked to severe anaphylactic reactions in paediatrics [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]. As in the case of sorbitol, it is not absorbed into the digestive tract, so it has laxative properties at high doses.</p></sec><sec id="sec3dot6dot4-pharmaceutics-13-00387"><title>3.6.4. Aspartame</title><p>Aspartame is an artificial sweetener that has 180 and 200 times more sweetener power than sucrose. Because of this, it is the most used sweetener in the pharmaceutical and food industry. It is a disaccharide made of an aspartic acid and a methyl phenylalanine ester. It is an excipient of mandatory declaration and its maximum dose has been set at 40 mg/kg body weight [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B35-pharmaceutics-13-00387" ref-type="bibr">35</xref>].</p><p>Phenylalanine is very harmful for patients with phenylketonuria, as well as for pregnant mothers who carry a foetus of such metabolopathy. The use of aspartame in patients with phenylketonuria should be avoided. The adverse effects of aspartame that have been described are: neurological (neurotoxicity, epilepsy, headache, panic attack and hallucinations), hypersensitivity reactions (vascular and granulomatous panniculitis) and cross-reaction with sulphonamides [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]. </p></sec><sec id="sec3dot6dot5-pharmaceutics-13-00387"><title>3.6.5. Saccharine</title><p>Saccharine is also an artificial sweetener 300&#x02013;600 times stronger that sucrose, but if not used properly it can leave a residual bitter taste. Your daily dose should not exceed 2.5 mg/kg body weight. It is recommended to limit the daily dose in children and pregnant women [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B48-pharmaceutics-13-00387" ref-type="bibr">48</xref>].</p><p>Currently, controversy about its safety remains present, as in adults it has been linked to bladder cancer when used at very high doses. Adverse effects of saccharine include hives, itching, photosensibilization, eczema, as well as nausea and diarrhoea [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>].</p></sec><sec id="sec3dot6dot6-pharmaceutics-13-00387"><title>3.6.6. Sucralose</title><p>Sucralose has a sweetener power between 100 and 300 times higher than sucrose. Its maximum daily dose is 15 mg/kg in weight.</p><p>Sucralose is a non-toxic compound and is also not irritating, but it is not considered totally inert. It can increase the expression of cell flow transport protein glycoprotein P and two cytochrome P450 isoforms, which are essential substances in the drug purification process.</p><p>Furthermore, sucralose alters the composition of the microbiome of the digestive tract, which ends up causing the reduction of the proportion of beneficial bacteria. In addition, if cooked at high temperatures, chloropropanol can form, which is a toxic compound. It can also alter the patient&#x02019;s levels of glucose, insulin and glucagon-like peptide type 1 (GLP-1) [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]. </p></sec></sec><sec id="sec3dot7-pharmaceutics-13-00387"><title>3.7. Surfactants</title><sec><title>Polysorbates </title><p>Polysorbates are partial esters of sorbitol fatty acids and their copolymerized anhydrous with ethylene oxide. They are used as dispersant agents, emulgents, non-ionic sanitary surfactants, solubilizers, and moisturizers, among other things. </p><p>In general, they are considered non-toxic and non-irritating. However, they have been associated with serious side effects, including deaths in under-weight neonates who received vitamin E preparations with this substance [<xref rid="B25-pharmaceutics-13-00387" ref-type="bibr">25</xref>]. In addition, polysorbate 80 has been associated with increased mortality in new-borns [<xref rid="B42-pharmaceutics-13-00387" ref-type="bibr">42</xref>].</p></sec></sec><sec id="sec3dot8-pharmaceutics-13-00387"><title>3.8. Colorants</title><p>Colorants are excipients used to facilitate the identification of the formula by parents and patients. The most commonly used dyes are whip dyes, quinolones, triphenylmethane and xanthines.</p><p>Tartrazine (yellow number 5) has been implicated in anaphylactic reactions, edema, asthma, bronchospasm, eosinophils, angioedema and hives in patients with sensitivity to it. It appears to cause histamine degranulation of mast cells [<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]. As a result, most global regulatory agencies restrict the use of dyes such as tartrazine, because azo dyes have been linked to hypersensitivity and ADHD reactions in children. These dyes can be replaced by plant dyes such as annatto, malt beta-carotene and turmeric and should not be used at all in paediatric formulations [<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>].</p></sec><sec id="sec3dot9-pharmaceutics-13-00387"><title>3.9. Excipients not Recommended in Paediatrics and Paediatric Formulations</title><p>To investigate the exposure of children to excipients not recommended at an early age, a compilation of paediatric formulations (nationally and internationally) was made (see <xref ref-type="app" rid="app3-pharmaceutics-13-00387">Appendix C</xref>, <xref ref-type="app" rid="app4-pharmaceutics-13-00387">Appendix D</xref>, <xref ref-type="app" rid="app5-pharmaceutics-13-00387">Appendix E</xref> and <xref ref-type="app" rid="app6-pharmaceutics-13-00387">Appendix F</xref>). As will be seen below, most of these formulations contain some excipient not recommended in paediatrics:</p><p>In <xref ref-type="app" rid="app3-pharmaceutics-13-00387">Appendix C</xref>, there is a summary table (<xref rid="pharmaceutics-13-00387-t0A2" ref-type="table">Table A2</xref>) of examples of solid and semi-solid medicines used in the paediatric population, marketed in Spain. Additionally, a list of excipients and relevant characteristics of the pharmaceutical form (PF) is shown (performed consultation of CIMA database, September 2020). It clearly shows that the reason such excipients are not recommended for the paediatric population is because of the adverse effects they may cause, which include:
<list list-type="bullet"><list-item><p>Approximately 100% of the formulations shown here carry at least one excipient not recommended for the paediatric population.</p></list-item><list-item><p>Benzalkonium chloride, methyl para hydroxybenzoate and propyl para hydroxybenzoate are some of the most commonly used preservatives in solid and semi-solid formulations for paediatric use, even though they are considered to be potentially toxic in neonates.</p></list-item><list-item><p>Sucrose, aspartame and mannitol are used as sweetener. 100% of the oral solid formulations collected in <xref rid="pharmaceutics-13-00387-t0A4" ref-type="table">Table A4</xref> carry at least one excipient of these: 40% of formulations carry mannitol and aspartame; 20% carry the 3 excipients; 20% sucrose and aspartame and the remaining 20% only sucrose.</p></list-item><list-item><p>Propylene glycol is another excipient commonly used in solid formulations as a solvent, moisturizer and preservative. Caution should be exercised in children under 4 years of age and neonates, as propylene glycols, at high doses, may cause alterations in the Central Nervous System, in addition to other side effects discussed in the previous sections of this paper.</p></list-item><list-item><p>Microcrystalline cellulose, methylcellulose and ethyl cellulose are one of the most commonly used excipients in solid formulations. They have no major side effects, but in high amounts they can cause a laxative effect.</p></list-item><list-item><p>Most of the solid formulations collected in <xref rid="pharmaceutics-13-00387-t0A2" ref-type="table">Table A2</xref> use flavourings such as grape essence, lemon flavouring, caramel cream aroma or orange essence, in order to achieve a better palatability. The main drawback of their incorporation into paediatric formulations is that they usually have a complex and poorly known composition [<xref rid="B49-pharmaceutics-13-00387" ref-type="bibr">49</xref>].</p></list-item><list-item><p>Lanolin is an excipient used in pastes and ointments, which are frequently used in the paediatric population. This excipient may cause skin hypersensitivity reactions, which is why caution should be exercised in patients with known sensitivity issues [<xref rid="B50-pharmaceutics-13-00387" ref-type="bibr">50</xref>].</p></list-item></list></p><p><xref ref-type="app" rid="app4-pharmaceutics-13-00387">Appendix D</xref> (<xref rid="pharmaceutics-13-00387-t0A3" ref-type="table">Table A3</xref>) lists marketed liquid formulations suitable for the paediatric population. Liquid formulations are the most common in paediatrics because of their easy administration. The need for at least one liquid formulation of any drug indicated in the paediatric population is becoming increasingly noticeable. Not all active principles are soluble or stable in water. Therefore, excipients are used in liquid formulations to improve the solubility of certain active principles and/or increase their stability. The problem is that most excipients found in adult formulations should not be used in paediatrics. However, as shown in <xref rid="pharmaceutics-13-00387-t0A3" ref-type="table">Table A3</xref>, there are a wide variety of marketed formulations indicated in paediatrics that contain these non-recommended excipients:<list list-type="bullet"><list-item><p>Ethanol, sorbitol and propylene glycol, despite being contraindicated in paediatrics, especially ethanol, are still included in some paediatric formulations.</p></list-item><list-item><p>The addition of non-recommended sweeteners, such as sucrose, sucralose or sodium saccharine, is also seen in these paediatric formulations.</p></list-item><list-item><p>The addition of preservatives in paediatric formulations should be avoided as much as possible, and if necessary, in the least amount. Parabens are among the safest preservatives in paediatrics, yet others that are not recommended are still used (e.g., <xref rid="pharmaceutics-13-00387-t0A3" ref-type="table">Table A3</xref>: sodium benzoate, benzoic acid and benzyl alcohol). Benzalkonium chloride, despite not being recommended for asthmatic patients, is used for the formulation of most eye drops, nasal drops and gothic drops.</p></list-item></list></p><p><xref ref-type="app" rid="app5-pharmaceutics-13-00387">Appendix E</xref> (<xref rid="pharmaceutics-13-00387-t0A4" ref-type="table">Table A4</xref>) and <xref ref-type="app" rid="app6-pharmaceutics-13-00387">Appendix F</xref> (<xref rid="pharmaceutics-13-00387-t0A5" ref-type="table">Table A5</xref>) provide examples of FDA-registered drugs (liquids and solids) and liquid formulations in paediatric use research, respectively. Like the other examples provided, these medicinal products and liquid formulations contain at least one excipient not recommended for the paediatric population, such as propylene glycol, polysorbates, methyl or propyl para hydroxybenzoate, benzyl alcohol, benzoic acid, ethanol or sucralose, among others.</p><list list-type="bullet"><list-item><p>Excipients not recommended for paediatric population are most commonly used in oral solutions and suspensions (referred to in <xref rid="pharmaceutics-13-00387-t0A4" ref-type="table">Table A4</xref> and <xref rid="pharmaceutics-13-00387-t0A5" ref-type="table">Table A5</xref>, propylene glycol, benzoic acid, polyethylene glycol, polysorbate 80 and sodium benzoate).</p></list-item><list-item><p>Like the other examples, there is also frequent use of sweeteners (fructose, sucrose, sucralose, aspartame and sodium saccharine).</p></list-item><list-item><p>Benzalkonium chloride is one of the most commonly used preservatives in ophthalmic and nasal drops, as shown in <xref rid="pharmaceutics-13-00387-t0A4" ref-type="table">Table A4</xref>. It is usually a safe excipient, but can cause serious adverse effects, such as bronchoconstriction in asthmatic patients, ototoxicity in erotic preparations or respiratory failure in infants who ingest this excipient, this adverse effect being the most severe.</p></list-item></list></sec></sec><sec id="sec4-pharmaceutics-13-00387"><title>4. Promising Pharmaceutical Form in the Paediatric Population: ODT and 3D Drug Printing</title><p>The development of Orally Disintegrating Tablets (ODT) has received greater interest among researchers and the pharmaceutical industry over the past decade. ODT tablets are designed to dissolve quickly upon contact with saliva, in the absence of additional water, compared to traditional tablets [<xref rid="B51-pharmaceutics-13-00387" ref-type="bibr">51</xref>].</p><p>ODT tablets offer several advantages, combining the properties of solid and liquid formulations. They are quickly ingested when inserted into the tongue, eliminating the need to chew the tablet, swallow it intact or take it with water. Currently, they are a widely accepted form of dosing, especially for patients who have difficulty swallowing (paediatric and geriatric), and for the treatment of patients where therapeutic compliance is difficult [<xref rid="B51-pharmaceutics-13-00387" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceutics-13-00387" ref-type="bibr">52</xref>].</p><p>As a result of the rapid disintegration of ODT tablets, the active substance comes into contact with taste buds, so a key aspect to consider in these formulations is palatability. It is necessary to mask the taste of bitter active ingredients in order to develop successful formulations. In the past, sweeteners and aromas were used as methods of flavour masking in dispersible or rapidly disaggregation tablets. However, these additives were not a sufficient means to completely mask the taste. Currently, with scientific and technological advances, different dosing alternatives are available to mask the taste, such as freeze-deriding, microencapsulation, fluid bed coating or coating in supercritical fluids [<xref rid="B51-pharmaceutics-13-00387" ref-type="bibr">51</xref>].</p><p>It should be mentioned that there is an innovative tool for pharmaceutical pre-formulation of ODT tablets. This tool makes it possible to predict whether a disintegrating excipient or a mixture of excipient powder + active substance is suitable for obtaining an oral dispersible tablet by direct compression or not: the new model SeDeM-ODT [<xref rid="B53-pharmaceutics-13-00387" ref-type="bibr">53</xref>].</p><p>The SeDeM-ODT model (based on the SeDeM expert system) indicates the ability of a powder to be compressed, providing the Good Compressibility and oral dispersibility Index (IGCB). This index is composed of six main factors which indicate whether a powder mixture has the ability to be compressed by direct compression. Furthermore, it indicates whether the tablets are suitable for formulation as oral dispersible tablets. Thus, the SeDeM-ODT model facilitates the selection of excipients with the appropriate properties to produce ODT tablets using direct compression technologies [<xref rid="B53-pharmaceutics-13-00387" ref-type="bibr">53</xref>].</p><p><xref ref-type="fig" rid="pharmaceutics-13-00387-f001">Figure 1</xref> will detail several special features and advantages of ODT tablets [<xref rid="B52-pharmaceutics-13-00387" ref-type="bibr">52</xref>,<xref rid="B54-pharmaceutics-13-00387" ref-type="bibr">54</xref>].</p><p><xref ref-type="fig" rid="pharmaceutics-13-00387-f002">Figure 2</xref> specifies the most noteworthy drawbacks of ODT tablets [<xref rid="B54-pharmaceutics-13-00387" ref-type="bibr">54</xref>].</p><p>On the other hand, the technical disadvantages associated with the manufacturing process of ODT tablets could be solved by three-dimensional drug printing technology. Generally speaking, this technology is supported by the following processes: a program capable of generating a file is required with the necessary information for printing the drug. This same program (also present on the computer that will control the printer) must be able to read the instructions contained in the generated file and convert it into precise commands for the 3D printer to generate the part [<xref rid="B55-pharmaceutics-13-00387" ref-type="bibr">55</xref>].</p><p>The response to drugs may be different among patients, due to inter-individual variability, caused by both genetic and environmental factors. Accordingly, &#x0201c;patient-specific&#x0201d; or &#x0201c;tailor-made&#x0201d; dosage concepts could be an alternative to mass production in the traditional pharmaceutical industry. In this approach, 3D printing has proven to be a manufacturing technique with great potential, as it allows the creation of three-dimensional objects, layer by layer, with total freedom of form and design. Thus, obtaining customized pharmaceutical forms is one of the main objectives of 3D printing in the pharmaceutical sector [<xref rid="B55-pharmaceutics-13-00387" ref-type="bibr">55</xref>].</p><p>Paediatric patients are one of the population groups with the greatest need for personalized dosing adapted to their requirements (age, weight, pathological status, etc.). However, most 3D printed drugs are solid oral formulations, which are not suitable for this population group. Medicinal gummies developed through 3D printing (tailor-made to the patient) could be a form of oral dosing suitable for paediatric patients, due to their striking appearance and pleasant organoleptic characteristics [<xref rid="B55-pharmaceutics-13-00387" ref-type="bibr">55</xref>].</p><p>New advances in obtaining medicines and medical devices, using 3D printing technology, have generated novel perspectives in the processes of obtaining these products. At present; however, several issues are perceived that will need to be resolved as the perfection and implementation of this technique progresses, in order to make it a common process of obtaining medicines and medical devices.</p></sec><sec sec-type="conclusions" id="sec5-pharmaceutics-13-00387"><title>5. Conclusions</title><p>The critical study suggests that excipients are often used at higher concentrations than recommended in international paediatric guidelines, and with inappropriate labelling, increasing the potential risks associated with the various excipients discussed [<xref rid="B26-pharmaceutics-13-00387" ref-type="bibr">26</xref>]. </p><p>Indeed, the pharmacokinetic and pharmacodynamic profiles of the child population vary substantially, with paediatric safety profiles related to the age and development of excipients often differing from those of adults [<xref rid="B48-pharmaceutics-13-00387" ref-type="bibr">48</xref>]. The most toxic excipients in neonates are known to be sodium benzoate, propylene glycol, methyl para hydroxybenzoate, propyl, sodium saccharine, benzyl alcohol, benzalkonium chloride, polysorbate 80 and ethanol [<xref rid="B56-pharmaceutics-13-00387" ref-type="bibr">56</xref>]. However, these excipients are used in formulations according to the study conducted.</p><p>European new-borns receive several potentially harmful pharmaceutical excipients: parabens, polysorbate 80, propylene glycol, benzoates, sodium saccharine, sorbitol, ethanol and benzalkonium chloride. According to the study conducted by Nellis and collaborators [<xref rid="B36-pharmaceutics-13-00387" ref-type="bibr">36</xref>], there are regional variations in the neonatal administration of these potentially harmful excipients. This suggests the possibility of reducing exposure to parabens, polysorbate 80, propylene glycol and sodium saccharine by replacing it with products without these excipients. However, a joint effort by the regulatory authorities on medicines, in particular the paediatric committees, will be necessary. Current therapeutic options for the paediatric population justify further toxicokinetic and drug safety studies so that they are tailored to the special needs of the paediatric population.</p><p>In general, there is little information regarding excipients in paediatrics. It is of the utmost importance to develop new research related to the safety and toxicity of excipients to reduce the prevalence of adverse effects in paediatric populations. Gallon formulators can formulate safer, more stable and higher quality products. Furthermore, the possible adverse effects of the active ingredients and the excipients used in the paediatric population should be reconsidered&#x02014;since excipients that are safe in adults&#x02014;may have potentially toxic effects in children.</p><p>Finally, the development of databases such as STEP is relevant and beneficial for the development and use of drugs in paediatrics. Additionally, the SEEN project is relevant both nationally and internationally, as it reveals the current status of excipients and takes into account the frequency and quantity (in terms of medicines given to new-borns and young children).</p></sec></body><back><ack><title>Acknowledgments</title><p>Renato Francis de Souza Pereira is thanked for helpful discussions during the finalization of this manuscript.</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, P.P.-L. and E.G.-M.; methodology, J.M.S.-N.; investigation, K.R. and B.C.-R.; writing&#x02014;original draft preparation, K.R. and B.C.-R.; writing&#x02014;review and editing, A.N.-R. and E.G.-M.; visualization, D.M.-F. and M.S.-P.; supervision, P.P.-L. and E.G.-M.; project administration, J.M.S.-N. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>The corresponding author, Blanca Chiclana-Rodr&#x000ed;guez, acknowledges the financial support of the Generalitat de Catalunya for the PhD scholarship FI-DGR (CVE-DOGC-A-19269057-2019). </p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on the Reference list.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><app-group><app id="app1-pharmaceutics-13-00387"><title>Appendix A. Purposes of the STEP Database</title><p>More specifically, the purposes of the STEP database are [<xref rid="B22-pharmaceutics-13-00387" ref-type="bibr">22</xref>] to:
<list list-type="order"><list-item><p>Serve as a public base for evidence regarding the safety and toxicity of excipients in order to allow the pharmaceutical industry, academics, pharmacists, physicians and regulators to make informed decisions. </p></list-item><list-item><p>Improve prospects of identifying potential security issues in the early stages of the development process when excipients are selected. </p></list-item><list-item><p>Help highlight any relationships between exposure and evidence of clinically significant toxicity in the paediatric age group in general, or in paediatric subpopulations. </p></list-item><list-item><p>Identify possible differences in expression, types or patterns of toxicity in children compared to adults. Provide a basis for assessing the need to generate new data for paediatric medicines (e.g., bridge studies, juvenile toxicity studies, etc.), in order to clarify what kind of new data, knowledge gaps or studies may be needed. </p></list-item><list-item><p>Support companies with their regulatory presentations with easily available information. </p></list-item><list-item><p>Support and improve research activities by providing a platform to share unreleased data and available data with corporate entities.</p></list-item></list></p></app><app id="app2-pharmaceutics-13-00387"><title>Appendix B</title><table-wrap id="pharmaceutics-13-00387-t0A1" orientation="portrait" position="anchor"><object-id pub-id-type="pii">pharmaceutics-13-00387-t0A1_Table A1</object-id><label>Table A1</label><caption><p>Most important characteristics of the excipients discussed in this paper (in alphabetical order).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Excipient</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Functions</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">DAI *</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Recommendations</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adverse Effects</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aspartame</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial Sweetener</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 mg/kg</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Contraindicated in patients with phenylketonuria</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Neurological involvement: neurotoxicity, epilepsy, headache, panic attack, hallucinations</p></list-item><list-item><label>-</label><p>Hypersensitivity reactions: vascular, granulomatous panniculitis</p></list-item><list-item><label>-</label><p>Cross reaction with sulfamides</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B35-pharmaceutics-13-00387" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benzalkonium chloride</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preservative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Caution in asthmatic patients</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Bronchoconstriction</p></list-item><list-item><label>-</label><p>Ototoxicity</p></list-item><list-item><label>-</label><p>Hypersensitivity</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benzyl alcohol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preservative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 mg/kg</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Contraindicated in children under 3 years of age by immature their metabolism</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">In new-borns and children under 3 years of age cause:<list list-type="simple"><list-item><label>-</label><p>Metabolic acidosis and respiratory depression</p></list-item><list-item><label>-</label><p>Intraventricular haemorrhage</p></list-item><list-item><label>-</label><p>Cerebral palsy and developmental delay</p></list-item><list-item><label>-</label><p>Hypersensitivity reactions</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B35-pharmaceutics-13-00387" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-13-00387" ref-type="bibr">36</xref>,<xref rid="B39-pharmaceutics-13-00387" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-13-00387" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-13-00387" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-13-00387" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-13-00387" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-13-00387" ref-type="bibr">44</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ethyl alcohol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solvent and preservative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 mg/kg/dose (&#x0003c;6 years)</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">Paediatric formulations should not exceed the following limits of ethanol:<list list-type="simple"><list-item><label>-</label><p>In children over 12 years of age: less than 10% (<italic>v/v</italic>)</p></list-item><list-item><label>-</label><p>In children 6&#x02013;12 years old: less than 5% (<italic>v/v</italic>)</p></list-item><list-item><label>-</label><p>In children under 6 years of age: less than 0.5 (<italic>v/v</italic>)</p></list-item></list></td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Hypoglycaemia, acidosis and hydroelectrolytic alterations</p></list-item><list-item><label>-</label><p>Stupor, coma respiratory and CNS depression, cardiovascular toxicity</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B17-pharmaceutics-13-00387" ref-type="bibr">17</xref>,<xref rid="B26-pharmaceutics-13-00387" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-13-00387" ref-type="bibr">27</xref>,<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B31-pharmaceutics-13-00387" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-13-00387" ref-type="bibr">32</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycerol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solvent, sweetener, viscosizer and preservative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 g/dose</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Caution in paediatric population</p></list-item><list-item><label>-</label><p>Do not exceed the safe daily dose (1.0&#x02013;1.5 g/kg body weight)</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Mucositis in the stomach</p></list-item><list-item><label>-</label><p>Diarrhoea and electrolyte disturbances</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B1-pharmaceutics-13-00387" ref-type="bibr">1</xref>,<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lactose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diluent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Caution in patients with lactose intolerance</p></list-item><list-item><label>-</label><p>Contraindicated in galactosemia</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">Symptoms of lactose intolerance: severe abdominal pain, flatulence, bloating or swelling and diarrhoea.<list list-type="simple"><list-item><label>-</label><p>Systemic symptoms such as muscle and joint pain and eczema</p></list-item><list-item><label>-</label><p>In children it can cause dehydration, bacterial proliferation and metabolic acidosis</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B1-pharmaceutics-13-00387" ref-type="bibr">1</xref>,<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parabens</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preservative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 mg/kg</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>It is recommended to avoid its use in neonates</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Cross hypersensitivity reactions in patients allergic to acetylsalicylic acid</p></list-item><list-item><label>-</label><p>Hyperbilirubinemia in new-borns</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B35-pharmaceutics-13-00387" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-13-00387" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phthalates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coating agents (plasticizers)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Not recommended for use in pregnant women or children under 3 years of age</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Anomalies in the development of the foetus: cleft palate and skeletal malformations. May lead to stillbirth</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polyethylene glycol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solvent, suspensor and viscosity agent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 mg/kg</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Caution in new-borns and infants</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Nephrotoxicity</p></list-item><list-item><label>-</label><p>Gastrointestinal disorders</p></list-item><list-item><label>-</label><p>Laxative effect</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B1-pharmaceutics-13-00387" ref-type="bibr">1</xref>,<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polysorbates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dispersing, emulgent, surfactants, solubilizing and moisturizing agents</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Caution in new-borns</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Serious adverse effects: deaths in low-weight neonates who received vitamin E preparations with polysorbates.</p></list-item><list-item><label>-</label><p>Polysorbate 80: increased mortality in new-borns</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-pharmaceutics-13-00387" ref-type="bibr">25</xref>,<xref rid="B42-pharmaceutics-13-00387" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Propyl gallate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antioxidant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Caution in new-borns</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>In neonates it can cause dermatitis, skin allergy and methemoglobinemia</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Propylene glycol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solvent, moisturizing and preservative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Neonates: 1 mg/kg</p></list-item><list-item><label>-</label><p>Under 5 years: 50 mg/kg</p></list-item><list-item><label>-</label><p>Adults: 500 mg/kg</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>It is recommended to avoid in children under 4 years of age because of lack of metabolic maturation</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>CNS depression</p></list-item><list-item><label>-</label><p>Laxative effect from high osmolality after oral administration</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B33-pharmaceutics-13-00387" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-13-00387" ref-type="bibr">34</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saccharine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sweetener</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5 mg/kg</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>It is recommended to limit the daily dose in pregnant women and children</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Urticaria, itching and eczema</p></list-item><list-item><label>-</label><p>Photosensitization</p></list-item><list-item><label>-</label><p>GI disturbances: Nausea and diarrhoea</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B48-pharmaceutics-13-00387" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sorbitol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sweetener and diluent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Children 0&#x02013;2 years 5 mg/kg</p></list-item><list-item><label>-</label><p>Over 2 years: 140 mg/kg</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Contraindicated in patients with fructose intolerance</p></list-item><list-item><label>-</label><p>Not recommended for use in patients with hypoglycaemia</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Gastrointestinal disorders</p></list-item><list-item><label>-</label><p>It can cause hepatic damage with comma and even death</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-13-00387" ref-type="bibr">30</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Starch</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diluent and added</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Conservation in dry environment</p></list-item><list-item><label>-</label><p>Well tolerated by children</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>In case of moisture, carcinogenic aflatoxins may occur</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sucralose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sweetener</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 mg/kg</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Caution in patients with metabolic disorders</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">Alters the composition of the digestive tract microbiome
<list list-type="simple"><list-item><label>-</label><p>At high temperatures chloropropanol may form</p></list-item><list-item><label>-</label><p>May alter glucose, insulin and GLP-1 *<sup>2</sup> levels</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sucrose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sweetener</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Not recommended for use in children with type I diabetes</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Dental damage</p></list-item><list-item><label>-</label><p>At very high doses on a daily basis I could be carcinogenic</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sulphites </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antioxidant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Avoid in asthmatic patients</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Hypersensitivity and bronchospasm reactions</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tartrazine, quinolines, triphenylmethane, xanthines </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorants</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>It is recommended not to use them in paediatric formulations</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1"><list list-type="simple"><list-item><label>-</label><p>Hypersensitivity reactions in patients&#x02019; sensitive to tartrazine</p></list-item><list-item><label>-</label><p>Azo colorants: cross-sensitivity reactions with acetylsalicylic acid</p></list-item></list> Erythromycin: photosensitization reactions
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thiomersal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preservative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Avoid use in vaccines as a preservative due to its side effects</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Hypersensitivity reactions</p></list-item><list-item><label>-</label><p>Autism spectrum disorders</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>* ADI: Admissible Daily Intake; *<sup>2</sup> GLP-1: Glucagon Like Peptide; NA: Not Available.</p></fn></table-wrap-foot></table-wrap></app><app id="app3-pharmaceutics-13-00387"><title>Appendix C</title><table-wrap id="pharmaceutics-13-00387-t0A2" orientation="portrait" position="anchor"><object-id pub-id-type="pii">pharmaceutics-13-00387-t0A2_Table A2</object-id><label>Table A2</label><caption><p>Examples of solid and semisolid medicines used in Spain for paediatric population: List of excipients and relevant characteristics of FF (Performed consultation of CIMA database, September 2020).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Pharmaceutical Form</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Excipients</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">API</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pharmaceutical Form Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SOLID <break/>PREPARATIONS </td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">POWDERS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Amoxicillin Normon 250 mg/5 mL EFG Oral Suspension Powder</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saccharose, Glucose, Methyl parahydroxybenzoate (E-218), Propyl parahydroxybenzoate (E-216), Anhydrous sodium citrate, Colloidal silica and Orange essence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amoxicillin</td><td rowspan="2" valign="middle" style="border-bottom:solid thin" align="left" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Powders are administered after prior dissolution.</p></list-item><list-item><label>-</label><p>They are little employees in the paediatric population; present the drawback that it is difficult to mask the bad taste.</p></list-item><list-item><label>-</label><p>Risk of accidental aspirations.</p></list-item><list-item><label>-</label><p>They are usually used in master formulation and for the administration of antacids.</p></list-item></list>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B57-pharmaceutics-13-00387" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceutics-13-00387" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 2: Azithromycin Sandoz 200 mg/5 mL EFG Oral Suspension Powder</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sucrose, Xanthan gum (E415), Hydroxypropyl cellulose, Anhydrous trisodium phosphate, Colloidal anhydrous silica (E551), Aspartame (E951), Aroma of caramel cream and Titanium dioxide (E171)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Azithromycin</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GRANULATED</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Paediatric Gelocatil 325 mg Granules</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Calcium carbonate, Sodium hydrogen carbonate, Citric acid anhydrous, Anhydrous sodium citrate, Aspartame (E-951), Sucrose, Mannitol (E-421), Amorphous silica, Glycerol die-stearate type 1, Croscarmellose sodium, Sodium glycolate starch type A (potato starch) gluten-free, Ethyl cellulose, Hydroxypropyl methylcellulose and Polyethylene glycol 400</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paracetamol</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Granules are more stable and fluid than powders.</p></list-item><list-item><label>-</label><p>The most used are effervescent granules, which in the presence of water react by releasing carbon dioxide, which protects the stomach and partly anesthetizes taste buds.</p></list-item><list-item><label>-</label><p>They should be completely dissolved prior to administration in order to reduce bicarbonate intake.</p></list-item><list-item><label>-</label><p>Children are often pleased by their resemblance to certain refreshing drinks.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B59-pharmaceutics-13-00387" ref-type="bibr">59</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">SOLID <break/>PREPARATIONS</td><td rowspan="2" align="center" valign="middle" colspan="1">ORAL <break/>DISPERSIBLE TABLETS (ODT)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Apiretal 325 mg oral dispersible tablets </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ethyl cellulose, Microcrystalline cellulose, Crospovidone, Aspartame (E-951), Colloidal silica, Mannitol, Talco, Magnesium stearate and Grape essence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paracetamol</td><td rowspan="2" valign="middle" align="left" colspan="1">As advantages of oral dispersible tablets, the following stand out: <list list-type="simple"><list-item><label>-</label><p>They combine the advantages of liquid forms and solid oral forms.</p></list-item><list-item><label>-</label><p>An exact dose may be given compared to liquids.</p></list-item><list-item><label>-</label><p>They have a pleasant taste, thus facilitating therapeutic compliance in the paediatric population.</p></list-item><list-item><label>-</label><p>No need to swallow the tablet or drink water; dissolves rapidly in saliva, being an appropriate choice for patients with swallowing problems, such as children or geriatric patients.</p></list-item><list-item><label>-</label><p>They are safe and effective and can be bio-equivalent with respect to conventional tablets.</p></list-item><list-item><label>-</label><p>They have rapid absorption and, therefore, a rapid introduction of the therapeutic effect.</p></list-item></list>Disadvantages include: <list list-type="simple"><list-item><label>-</label><p>The lack of mechanical resistance presented by traditional tablets.</p></list-item><list-item><label>-</label><p>The possibility of physical instability in excess moisture.</p></list-item><list-item><label>-</label><p>ODTs require special conditioning to ensure their stability.</p></list-item></list></td><td rowspan="2" align="center" valign="middle" colspan="1">[<xref rid="B54-pharmaceutics-13-00387" ref-type="bibr">54</xref>,<xref rid="B60-pharmaceutics-13-00387" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceutics-13-00387" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Example 2: Junifen 200 mg lemon-flavored oral dispersible tablets</td><td align="center" valign="middle" rowspan="1" colspan="1">Ethyl cellulose, Precipitated silicon dioxide, Hypromellose, Mannitol, Aspartame (E-951), Croscarmellose sodium, Magnesium stearate and Lemon flavouring</td><td align="center" valign="middle" rowspan="1" colspan="1">Ibuprofen</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SOLID <break/>PREPARATIONS</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SUPPOSITORIES</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Febectal Infants 150 mg Suppositories</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Colloidal anhydrous silica, Solid semi-synthetic glycerides</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Paracetamol</td><td valign="middle" style="border-top:solid thin;border-bottom:solid thin" align="left" rowspan="1" colspan="1">As advantages, the following stand out:<list list-type="simple"><list-item><label>-</label><p>Generally, they avoid gastric intolerance problems.</p></list-item><list-item><label>-</label><p>They are of interest when the medicine is inactive orally, the patient is unconscious or are children who refuse to swallow the medication.</p></list-item><list-item><label>-</label><p>They avoid inactivation by the effect of first liver step.</p></list-item></list>Disadvantages include: <list list-type="simple"><list-item><label>-</label><p>Reproducible behaviour can only be obtained if absorbed into an area two centimetres from the end of the rectum.</p></list-item><list-item><label>-</label><p>Absorption of the active substance may be erratic.</p></list-item><list-item><label>-</label><p>As it avoids the effect of first liver step, it can increase the possibility of poisoning.</p></list-item><list-item><label>-</label><p>In certain cultures, it is a form that is not well accepted socially.</p></list-item></list></td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B62-pharmaceutics-13-00387" ref-type="bibr">62</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SEMI-SOLID PREPARATIONS </td><td align="center" valign="middle" rowspan="1" colspan="1">GELS </td><td align="center" valign="middle" rowspan="1" colspan="1">Example 1: Fenistil 1 mg/g Gel</td><td align="center" valign="middle" rowspan="1" colspan="1">Benzalkonium chloride, Disodium edetate, Carbomer, Sodium hydroxide, Propylene glycol amd Purified water</td><td align="center" valign="middle" rowspan="1" colspan="1">Dimethindene maleate</td><td valign="middle" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>It is a semi-soft transparent colloid, with a large proportion of liquids.</p></list-item><list-item><label>-</label><p>Low penetration power.</p></list-item><list-item><label>-</label><p>Many incompatibilities with active substances.</p></list-item><list-item><label>-</label><p>It is easy to apply, pleasant and soothing for its refreshing properties.</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B63-pharmaceutics-13-00387" ref-type="bibr">63</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">SEMI-SOLID PREPARATIONS </td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CREAMS </td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Perme-Cure 5% Cream </td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Butylhydroxytoluene <break/>(E-321), Castor Oil, Deionized water, Steareth-2, Ceteareth-2-Phosphate, Sosa to the 20 %, Vitamin E acetate, Phenonip, Citric acid, Disodium edetate and Scent</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Permethrin cis:trans (25:75)</td><td valign="middle" style="border-top:solid thin;border-bottom:solid thin" align="left" rowspan="1" colspan="1">As advantages, the following stand out:<list list-type="simple"><list-item><label>-</label><p>Comfortable and easy application.</p></list-item><list-item><label>-</label><p>Provide a controlled release of the active substance.</p></list-item><list-item><label>-</label><p>They act as emollients and moisturizers, due to their composition</p></list-item></list></td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B64-pharmaceutics-13-00387" ref-type="bibr">64</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OINTMENTS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Oftacilox 3 mg/g Ophthalmic Ointment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liquid paraffin and White Vaseline </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ciprofloxacin</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Ointments are forms of external use intended to be administered by gentle friction on a surface of the body, to achieve a local action or with the aim of penetrating the drug through it.</p></list-item><list-item><label>-</label><p>In many cases, the topical route is a route of absorption comparable to oral or other, so the dosage and duration of treatment must be very well specified. New-borns and infants have a very increased skin-to-weight ratio. Coupled with the fact that at this age the skin is very permeable, it makes them especially vulnerable to toxic frames by ointments.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B65-pharmaceutics-13-00387" ref-type="bibr">65</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PASTES </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Anti-congestive Cusi (Paste Lassar)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lanolin (wool fat), Liquid Vaseline and Stringy Vaseline</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Zinc oxide</p></list-item><list-item><label>-</label><p>Corn starch</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>This is a suspended ointment.</p></list-item><list-item><label>-</label><p>They are used when you want to locate the action of the active substance to a specific area, as they are irritating and staining.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B66-pharmaceutics-13-00387" ref-type="bibr">66</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SEMI-SOLID PREPARATIONS<break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NON-CREAM EMULSIONS<break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Lactisona 10 mg/mL Skin Emulsion<break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carbomer 940, 1,3-dimethylol-5,5-dimethyl hydantoin, Dihydro-acetic acid, Pyrrolidone sodium carboxylate, Lactic acid, <break/>Sodium hydroxide, Stearyl alcohol, Glycerol stearate, Cetyl alcohol, Isopropyl palmitate, Mineral oil, Myristyl lactate, Fragrance and Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydrocortisone</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Emulsions are a dispersed system, stabilized by the addition of an adequate emulsifier, two immiscible phases, where both the internal and external phases are liquid.</p></list-item><list-item><label>-</label><p>The emulsions enable fat-soluble and water-soluble active ingredients to come into contact with the skin simultaneously, encompassing each of them in the phase of the emulsion for which they have the greatest affinity.</p></list-item><list-item><label>-</label><p>Patients or users of topical application preparations often prefer emulsion vehicles to those of any kind.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-pharmaceutics-13-00387" ref-type="bibr">50</xref>,<xref rid="B67-pharmaceutics-13-00387" ref-type="bibr">67</xref>]</td></tr></tbody></table></table-wrap></app><app id="app4-pharmaceutics-13-00387"><title>Appendix D</title><table-wrap id="pharmaceutics-13-00387-t0A3" orientation="portrait" position="anchor"><object-id pub-id-type="pii">pharmaceutics-13-00387-t0A3_Table A3</object-id><label>Table A3</label><caption><p>Examples of liquid medicines used in paediatrics: List of excipients and relevant characteristics of Pharmaceutical Form.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Pharmaceutical Form</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Excipients</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">API</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pharmaceutical Form Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LIQUID <break/>PREPARATIONS</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ORAL SOLUTIONS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Diazepam 2 mg/5 mL Solution without sugar</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium Docusate, Aluminium silicate and Magnesium, Propylene glycol, Raspberry Flavour, Sodium Saccharine, Precool Erythrosine (E127), Sorbic Acid (E200), Propyl para hydroxybenzoate, Methyl para hydroxybenzoate, Sorbitol, Liquid (Non-Crystalized) (E420) and Glycerol (E422)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diazepam </td><td rowspan="2" valign="middle" style="border-bottom:solid thin" align="left" colspan="1">As advantages, the following stand out: <list list-type="simple"><list-item><label>-</label><p>Release of the active substance(s) much faster than in solid forms.</p></list-item><list-item><label>-</label><p>The dosages are correctly expressed in milligrams, micrograms and U/mL, allowing them to be adapted to the child&#x02019;s weight.</p></list-item><list-item><label>-</label><p>Easy and comfortable dosing, as it is in volume (spoons, drops, etc.)</p></list-item><list-item><label>-</label><p>Less irritation effect if it is an aggressive medicine, at the gastric level, as it is dampened by dilution.</p></list-item><list-item><label>-</label><p>Solutions, suspensions or emulsions are obtained, depending on the size of the particles of the internal phase.</p></list-item></list>As disadvantages they present:</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B49-pharmaceutics-13-00387" ref-type="bibr">49</xref>,<xref rid="B68-pharmaceutics-13-00387" ref-type="bibr">68</xref>,<xref rid="B69-pharmaceutics-13-00387" ref-type="bibr">69</xref>,<xref rid="B70-pharmaceutics-13-00387" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 2: Paracetamol Level 100 mg/mL Oral Solution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Citric acid, Sodium hydroxide, Sucrose, Propylene glycol, Macrogol, Strawberry Essence, Cochineal Red A (Ponceau 4R) (E-124), Hydrochloric Acid 5 N and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paracetamol </td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 3: Diazepam Intensol&#x02122; Oral Solution 5 mg/mL<break/>* <italic>Do not use in children under 6 months of age</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alcohol, Yellow D&#x00026;C 10, Polyethylene glycol, Succinic Acid and Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diazepam </td><td rowspan="2" valign="middle" style="border-bottom:solid thin" align="left" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Greater ease and possibility of contamination than solid pharmaceutical forms, which forces the addition of preservatives.</p></list-item></list>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B71-pharmaceutics-13-00387" ref-type="bibr">71</xref>,<xref rid="B72-pharmaceutics-13-00387" ref-type="bibr">72</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 4: Prednisolone 10 mg/mL Oral Solution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium Methyl para hydroxybenzoate, Sodium Propyl para hydroxybenzoate, Glycerol, Sodium Saccharine, Sodium Edetate, Sodium Aqueous solutions of medicinal substances that areDihydrate, Orange flavour (contains propylene glycol), Sodium hydroxide and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prednisolone</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LIQUID <break/>PREPARATIONS</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ORAL <break/>SOLUTIONS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 5: Ozalin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Citric acid monohydrate, Gamma-cyclodextrin, Sucralose, Orange flavour (contains 70&#x02013;80% ethanol), Sodium hydroxide, injectable water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Midazolam </td><td rowspan="3" valign="middle" style="border-bottom:solid thin" align="left" colspan="1">
<italic>See &#x0201c;Pharmaceutical Form Characteristics (Oral Solutions)&#x0201d; section of the previous page</italic>
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B73-pharmaceutics-13-00387" ref-type="bibr">73</xref>,<xref rid="B74-pharmaceutics-13-00387" ref-type="bibr">74</xref>,<xref rid="B75-pharmaceutics-13-00387" ref-type="bibr">75</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 6: Flumil 20 mg/mL Oral Solution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Para-Hydroxybenzoate Methyl (E218), Sodium Benzoate (E211), Sodium Edetate, Carmellose Sodium, Sodium saccharine, Sodium Cyclamate, Sucralose, Raspberry Aroma, Sodium Hydroxide and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acetyl cysteine</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 7: Paediatric Lanacordin 0.05 mg/mL <break/>* <italic>Including newborns and premature</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sucrose, Ethanol, Tartrazine (E-102), Anhydrous Sodium Phosphate, Citric Acid (E-330), Methyl Hydroxybenzoate, Lime Essential Oil, Propylene glycol (E-1520) and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Digoxin</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LIQUID <break/>PREPARATIONS</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ORAL <break/>SUSPENSIONS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Paracetamol 120 mg/5 mL Oral Suspension</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Propylene glycol, Methyl Hydroxybenzoate, Propyl Hydroxybenzoate, Xanthan Gum, 70% Sorbitol Solution, Sucrose, Mango flavour and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paracetamol </td><td rowspan="2" valign="middle" style="border-bottom:solid thin" align="left" colspan="1">As advantages, the following stand out: <list list-type="simple"><list-item><label>-</label><p>Suspensions are the ideal pharmaceutical forms for the administration of non-water-soluble active ingredients.</p></list-item><list-item><label>-</label><p>The fact that the active substance is insoluble, allows an extension of the time of action in the body.</p></list-item><list-item><label>-</label><p>It is easier to mask the taste than in syrups and elixirs (more pleasant for children).</p></list-item><list-item><label>-</label><p>Good relative bioavailability.</p></list-item></list></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B76-pharmaceutics-13-00387" ref-type="bibr">76</xref>,<xref rid="B77-pharmaceutics-13-00387" ref-type="bibr">77</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 2: Junior Parapaed 120 mg/5 mL Oral Suspension</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ethanol, Polysorbate 80, Glycerol, Magnesium and Aluminium silicate, Liquid maltitol syrup, Sodium saccharine (E954), xanthan gum, cherry flavour, sodium benzoate, Citric acid monohydrate and purified water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paracetamol</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LIQUID <break/>PREPARATIONS</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ORAL <break/>SUSPENSIONS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 3: Mycostatin 100.000 UI/mL Oral Suspension</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sucrose, 96% ethanol, Carmellose sodium, Cinnamic aldehyde, Mint Essence, Cherry Aroma, Anhydrous Disodium Hydrogen phosphate, Glycerol (E-422), Methyl para hydroxybenzoate, Propyl para hydroxybenzoate, Sodium Hydroxide, Hydrochloric Acid and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nystatin </td><td rowspan="2" valign="middle" style="border-bottom:solid thin" align="left" colspan="1">Disadvantages include:<list list-type="simple"><list-item><label>-</label><p>Sediment formation.</p></list-item><list-item><label>-</label><p>Difficulty removing the viscosity of the vehicle.</p></list-item><list-item><label>-</label><p>Less stability than solid shapes, solutions and emulsions.</p></list-item><list-item><label>-</label><p>The use of very fine particle size causes the formation of sediments that are very difficult to re-suspend.</p></list-item></list><italic>It is important to shake the suspension for at least 10 s before use</italic>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B78-pharmaceutics-13-00387" ref-type="bibr">78</xref>,<xref rid="B79-pharmaceutics-13-00387" ref-type="bibr">79</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 4: Paediatric Algidrin 20 mg/mL Oral Suspension <break/>* <italic>Do not give to children under 3 months of age</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microcrystalline cellulose, Carboxymethylcellulose sodium, Sorbitol (E-420), Maltitol (E-965), Beta-cyclodextrin, Sodium Saccharine, Sucralose (E-955), Forest Fruit Aroma, Allura AC Red Colouring (E-129), Methyl para hydroxybenzoate, Ethyl para hydroxybenzoate, Propyl para hydroxybenzoate and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ibuprofen (Lysine)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LIQUID <break/>PREPARA-TIONS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ORAL <break/>SUSPEN-SIONS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 5: Paediatric Septrin 8 mg/40 mg/mL Oral Suspension<break/><italic>* Suitable for infants from 6 weeks of age</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sorbitol, Glycerol (E-422), Dispersible Cellulose, Carmellose Sodium, Polysorbate 80, Methyl para hydroxybenzoate, Sodium Benzoate, Sodium Saccharine, Banana flavour (Propylene Glycol E-1520, Sodium Citrates E-331), Ethanol 96&#x000b0;, Vanilla flavour (Benzyl Alcohol, Caramel Colour E-150d, Propylene Glycol E-1520, Glycerol E-422, Water), Purified Water.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Trimetho-prim</p></list-item><list-item><label>-</label><p>Sulfametho-xazole</p></list-item></list>
</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<italic>See &#x0201c;Pharmaceutical Form Characteristics (Oral Suspension)&#x0201d; section of the previous page</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B80-pharmaceutics-13-00387" ref-type="bibr">80</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LIQUID PREPARATIONS</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ELIXIRS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Paracetamol Elixir Pedi&#x000e1;trico 120 mg/5 mL </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ethanol 96&#x000b0; (10% <italic>v</italic>/<italic>v</italic>), Propylene glycol, Inverted Syrup, Amaranth Solution (E123), Glycerol, Glycerine, Chloroform and Concentrated Raspberry Juice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paracetamol </td><td rowspan="2" valign="middle" style="border-bottom:solid thin" align="left" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Hydro alcoholic solution sweetened with low sugar.</p></list-item><list-item><label>-</label><p>It has high alcohol content, which will have to be considered at certain ages, as it can create addition or generate other side effects: drowsiness and various dangers arising.</p></list-item></list>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B81-pharmaceutics-13-00387" ref-type="bibr">81</xref>,<xref rid="B82-pharmaceutics-13-00387" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 2: Lanoxin Elixir<break/><italic>* Fit for premature neonates</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Methyl Hydroxybenzoate, Sucrose, Sodium Phosphate Anhydrous, Citric Acid Monohydrate, Quinine Yellow, Ethanol (96%), Propylene Glycol, Lime flavour and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Digoxin</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SYRUPS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Daleron Syrup 120 mg/5 mL </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sorbitol, Glycerol, Xanthan Gum, Maltitol, Microcrystalline Cellulose, Croscarmellose Sodium, Sodium Benzoate, Citric Acid, Pineapple flavour, Riboflavin and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paracetamol</td><td rowspan="2" valign="middle" style="border-bottom:solid thin" align="left" colspan="1"><list list-type="simple"><list-item><label>-</label><p>Syrups are liquid solutions with sweetening, flavouring and viscosizing properties. They are almost saturated aqueous solutions of sucrose (64%).</p></list-item></list>They have the following drawbacks: <list list-type="simple"><list-item><label>-</label><p>Alterations that require the incorporation of preservatives and specify</p></list-item></list></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B83-pharmaceutics-13-00387" ref-type="bibr">83</xref>,<xref rid="B84-pharmaceutics-13-00387" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 2: Loratadine 5 mg/mL Syrup Oral Solution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Propylene glycol, Glycerol, Sodium Benzoate, Citric Acid Monohydrate, Sucrose, Peach flavour and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Loratadine </td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LIQUID<break/>PREPARA-TIONS</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SYRUPS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 3: Polaramine 0.4 mg/mL Syrup<break/><italic>* Not suitable for children under 2 years old</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ethanol, Sucrose, Sodium Citrate, Sodium Chloride, Sorbitol, Methyl paraben, Propyl paraben, Menthol, Apricot flavour, Orange flavour, Ponceau 4R Colouring (E-124) and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dexchlorpheni-ramine maleate</td><td rowspan="2" valign="middle" align="left" style="border-bottom:solid thin" colspan="1">See &#x0201c;Pharmaceutical Form Characteristics (Syrups)&#x0201d; section of the previous page</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B85-pharmaceutics-13-00387" ref-type="bibr">85</xref>,<xref rid="B86-pharmaceutics-13-00387" ref-type="bibr">86</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 4: Paediatric Mucosan 3 mg/mL Syrup</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydroxyethyl cellulose, Sucralose, Benzoic Acid (E-210), Wild Berry Aroma, Vanilla Aroma and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ambroxol hydrochloride</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LIQUID<break/>PREPARATIONS</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ORAL <break/>DROPS IN <break/>SOLUTION </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Romillary 15 mg/mL Oral drops in Solution<break/>* Not recommended for use in children under 2 years of age </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Propylene glycol, anhydrous ethanol, Flavourings: coriander oil, orange essential oil and lemon tetraroma, macrogol glycerol ricinolate (chromophore EL), Methyl para hydroxybenzoate, Propyl para hydroxybenzoate, sodium saccharine, citric acid monohydrate, sodium hydroxide and purified water </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydrobromide dextromethorphan </td><td rowspan="2" valign="middle" style="border-bottom:solid thin" align="left" colspan="1"><list list-type="simple"><list-item><label>-</label><p>Oral liquid medicinal products may be placed on the market in the form of drops for children of different ages.</p></list-item><list-item><label>-</label><p>The main benefits of drops are low dosing volume, facilitating swallowing and dosing flexibility.</p></list-item></list>As disadvantages, the following stand out: the variation of the droplet size and errors in the count, which would result in an incorrect dosage. This can cause serious problems in those medicines with a narrow therapeutic margin. </td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B87-pharmaceutics-13-00387" ref-type="bibr">87</xref>,<xref rid="B88-pharmaceutics-13-00387" ref-type="bibr">88</xref>,<xref rid="B89-pharmaceutics-13-00387" ref-type="bibr">89</xref>,<xref rid="B90-pharmaceutics-13-00387" ref-type="bibr">90</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 2: Alerlisin 10 mg/mL Oral Drops in Solution<break/><italic>* Do not use in children under 2 years of age</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycerol, Propylene glycol (E-1520), Sodium Saccharine, Methyl para hydroxybenzoate, Propyl para hydroxybenzoate, Sodium Acetate, Glacial Acetic Acid and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetirizine hydrochloride</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LIQUIDPREPARA-TIONS</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ORAL DROPS IN SOLUTION</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 3: Paediatric Cleboril 62.5 g Oral Drops in Solution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benzoic acid (E-210), Sodium hydroxide and purified water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clebopride malate</td><td rowspan="3" valign="middle" style="border-bottom:solid thin" align="left" colspan="1">See &#x0201c;Pharmaceutical Form Characteristics (Oral Drops in Solution)&#x0201d; section of the previous page</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B91-pharmaceutics-13-00387" ref-type="bibr">91</xref>,<xref rid="B92-pharmaceutics-13-00387" ref-type="bibr">92</xref>,<xref rid="B93-pharmaceutics-13-00387" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 4: Fluor Lacer 1.4 mg/mL Oral Drops <break/>* Indicated for tooth decay prophylaxis in children 1&#x02013;6 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium Saccharine, Propylene glycol, Methyl para hydroxybenzoate, Propyl para hydroxybenzoate, Disodium edetate, Cochineal Red Colouring (E-124), Strawberry Aroma and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium Fluoride </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 5: Hydropolivit Oral Drops in Solution<break/><italic>* Recommended for children over 2 years old</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Propylene glycol, Polysorbate 80, Sorbitol 70% (E-420), Glycerol (E-422), Sodium Saccharine, Sodium Edetate, Monothioglycerol, Methyl para hydroxybenzoate, Butylhydroxyanisole (E-320), Banana Essence, Vanilla Essence, Sodium Hydroxide and Purified Water</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-Retinol palmitate<break/>Cholecalciferol <break/>Alpha-tocopherol acetate<break/>Riboflavin <break/>Pyridoxine hydrochloride <break/>Ascorbic acid <break/>Biotin<break/>Nicotinamide</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LIQUID PREPARATIONS</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ORAL DROPS INSUSPENSION</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Zamene 22.75 mg/mL Oral Drops in Suspension<break/>* Special interest in paediatrics. <break/>Not recommended in children under 2 months of age.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aluminium and Magnesium silicate, Carboxymethylcellulose sodium, Benzyl alcohol, 70% Sorbitol, Polysorbate 80, Acetic Acid and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deflazacort</td><td rowspan="2" valign="middle" style="border-bottom:solid thin" align="left" colspan="1">They have the same characteristics as oral drops in solution</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B94-pharmaceutics-13-00387" ref-type="bibr">94</xref>,<xref rid="B95-pharmaceutics-13-00387" ref-type="bibr">95</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 2: Dezacor 22.75 mg/mL Oral Drops in Suspension<break/>* Special interest in paediatrics. <break/>Not recommended in children under 2 months of age.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sorbitol solution 70%, Carboxymethylcellulose sodium, Aluminium silicate and magnesium, Polysorbate 80, Benzyl Alcohol, Sucralose, Tropical Fruit Aroma, Citric Acid Monohydrate, Sodium Hydroxide and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deflazacort</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">OPHTHALMIC DROPS OR COLLYRIUMS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Atropine BP 1.0% (<italic>w</italic>/<italic>v</italic>)/Vistatropin 1.0% (<italic>w</italic>/<italic>v</italic>) Eye drops in solution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benzalkonium chloride in solution and purified water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atropine sulphate</td><td rowspan="2" valign="middle" style="border-bottom:solid thin" align="left" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Sterile solutions aimed at exercising their action in the conjunctiva.</p></list-item><list-item><label>-</label><p>May cause systemic side effects, especially observed after instillation of mydriatic eye drops.</p></list-item></list>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B68-pharmaceutics-13-00387" ref-type="bibr">68</xref>,<xref rid="B96-pharmaceutics-13-00387" ref-type="bibr">96</xref>,<xref rid="B97-pharmaceutics-13-00387" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 2: Chibroxin 3 mg/mL Collyrium in solution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium Acetate, Benzalkonium Chloride, Disodium Edetate, Concentrated Hydrochloric Acid, Sodium Chloride and Water for Injections</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Norfloxacin </td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LIQUID PREPARATIONS</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">NASAL DROPS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Rhinovin<sup>&#x000ae;</sup> Children&#x02019;s 0.5 mg/mL Nasal Drops in Solution<break/><italic>* Do not use in children under 6 years of age</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dihydrogen phosphate of sodium dihydrate, disodium phosphate dodecahydrate, disodium Edetate, Benzalkonium Chloride, Sorbitol (E420), Hypromellose, Sodium Chloride and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Xylometazoline hydrochloride</td><td rowspan="2" valign="middle" style="border-bottom:solid thin" align="left" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Aqueous solutions of medicinal substances that are instilled through the nose and act on the nasal mucosa.</p></list-item><list-item><label>-</label><p>Oils are contraindicated in their formulation, because the ciliary function has to be maintained.</p></list-item><list-item><label>-</label><p>It can be an excellent route of systemic administration, in addition to use as a topical route (there are promising studies with insulin and other substances).</p></list-item></list>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B68-pharmaceutics-13-00387" ref-type="bibr">68</xref>,<xref rid="B98-pharmaceutics-13-00387" ref-type="bibr">98</xref>,<xref rid="B99-pharmaceutics-13-00387" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 2: Utabon Children 0.25 mg/mL Nasal Drops in Solution<break/><italic>* Do not use in children under 6 years of age</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benzalkonium chloride, anhydrous disodium hydrogen phosphate, Sodium dihydrogen phosphate dihydrate, glycine (E-640), Sorbitol (E-420) and Purified water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oxymetazoline hydrochloride</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">OTIC DROPS </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Otic cetraxal 3 mg/mL Otic drops en Soluci&#x000f3;n<break/><italic>* Indicated in adults and child</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lactic acid, Povidone, Anhydrous Glucose, Propylene glycol, Methyl para hydroxybenzoate, Propyl para hydroxybenzoate, Hydrochloric Acid and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ciprofloxacin </td><td rowspan="2" valign="middle" style="border-bottom:solid thin" align="left" colspan="1"><list list-type="simple"><list-item><label>-</label><p>Liquid preparations to apply to the middle and outer ear.</p></list-item><list-item><label>-</label><p>The active substances are usually antiseptics, local anaesthetics and antibiotics.</p></list-item></list>Excipients have to be suitable to achieve a pH of 5&#x02013;6.</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B100-pharmaceutics-13-00387" ref-type="bibr">100</xref>,<xref rid="B101-pharmaceutics-13-00387" ref-type="bibr">101</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 2: Otix Otic Drops in Solution<break/>* Do not administer in children under 2 years of age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benzalkonium Chloride, Sulphuric acid, Sodium Chloride, Sodium Hydroxide, Tribasic Sodium Citrate, Polysorbate 80, Citric Acid and Purified Water</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Dexamethasone sodium phosphate</p></list-item><list-item><label>-</label><p>Trimethoprim</p></list-item><list-item><label>-</label><p>Polymyxin B sulphate</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LIQUID PREPARATIONS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OTIC DROPS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 3: Ciproxin Simple 3 mg/mL Otic Drops in Solution<break/>* Not recommended for children under 1 year old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benzalkonium Chloride, Sodium Acetate Trihydrate, Glacial Acetic Acid, Mannitol (E-421), Disodium Edetate, Hydrochloric Acid and/or Sodium Hydroxide and Purified Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ciprofloxacin hydrochloride</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">See &#x0201c;Pharmaceutical Form Characteristics (Otic Drops)&#x0201d; section of the previous page</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B102-pharmaceutics-13-00387" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PARENTERAL PREPARATIONS FOR<break/>INJECTION </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">INTRAVENOUS </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Example 1: Digoxin Kern Pharma 0.25 mg/mL solution for injection<break/>* including premature neonates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ethanol, Propylene Glycol, Citric Acid Anhydrous, Bi-sodium Anhydrous Phosphate and Bi-distillate Water.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Digoxin</td><td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>The intravenous line is the one of choice in new-borns and in emergencies. It achieves a quick effect and are easy to dos.</p></list-item><list-item><label>-</label><p>Risk of infection and can be painful at times and cause difficult-to-resolve injuries.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>,<xref rid="B103-pharmaceutics-13-00387" ref-type="bibr">103</xref>]</td></tr></tbody></table></table-wrap></app><app id="app5-pharmaceutics-13-00387"><title>Appendix E</title><table-wrap id="pharmaceutics-13-00387-t0A4" orientation="portrait" position="anchor"><object-id pub-id-type="pii">pharmaceutics-13-00387-t0A4_Table A4</object-id><label>Table A4</label><caption><p>Examples of FDA-registered drugs used in paediatrics (FDA and DAILYMED database consultation October 2020).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Pharmaceutical Form</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Excipients</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Active Principle</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LIQUID PREPARATIONS</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ORAL <break/>SOLUTIONS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abilify Solution Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disodium edetate, fructose (200 mg per mL), glycerine, dl-lactic acid, methylparaben, propylene glycol, propylparaben, sodium hydroxide, sucrose (400 mg per mL), and purified water. The Oral solution is flavoured with natural orange cream and other natural flavours</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aripiprazole</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 to 18 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-pharmaceutics-13-00387" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Demerol Solution Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benzoic acid, flavour, liquid glucose, purified water, saccharin sodium</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Meperidine hydrochloride</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adult and paediatric patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B105-pharmaceutics-13-00387" ref-type="bibr">105</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diazepam Oral Solution (Lannett Company)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polyethylene glycol, propylene glycol, non-crystallizing sorbitol solution, sodium citrate anhydrous, bitterness modifier flavour, anhydrous citric acid, peppermint flavour, mint flavour, FD&#x00026;C Network No. 40 aluminium lake, D&#x00026;C Yellow No. 10 aluminium lake and purified water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diazepam (5 mg/5 mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Children from 6 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B106-pharmaceutics-13-00387" ref-type="bibr">106</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ORAL <break/>SUSPENSIONS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adzenys ER (Extend release)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Purified water, sorbitol, propylene glycol, xanthan gum, natural orange flavour, methacrylic acid and methyl methacrylate copolymer, sodium polystyrene sulfonate, vegetable oil, triethyl citrate, methylparaben, citric acid, sucralose, propylparaben, orange colour (FD&#x00026;C Yellow No. 6), and polyethylene glycol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amphetamine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 to 17 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B107-pharmaceutics-13-00387" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Children&#x02019;s Tylenol<sup>&#x000ae;</sup> Cold + Cough + Sore Throat Oral Suspension</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anhydrous citric acid, D&#x00026;C network No. 33, FD&#x00026;C network No. 40, flavours, glycerine, microcrystalline cellulose and sodium carboxymethyl cellulose, purified water, sodium benzoate, sorbitol solution, sucralose, xanthan gum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acetaminophen 160 mg<break/>Dextromethorphan hydrobromide 5 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 to 11 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B108-pharmaceutics-13-00387" ref-type="bibr">108</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ORAL SUSPENSIONS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dyanavel XR (Extend release)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anhydrous citric acid, bubble-gum flavour, glycerine, methylparaben, modified food starch, polysorbate 80, povidone, polyvinyl acetate, propylparaben, sodium lauryl sulphate, sodium polystyrene sulfonate, sucralose, triacetin and xanthan gum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amphetamine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Children from 6 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B109-pharmaceutics-13-00387" ref-type="bibr">109</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SYRUPS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Midazolam hydrochloride syrup</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anhydrous Citric Acid, D&#x00026;C Network No. 33, edetate disodium, glycerine, sodium benzoate, sorbitol, Water, Hydrochloric Acid, Sodium Citrate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Midazolam hydrochloride </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Children from 6 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B110-pharmaceutics-13-00387" ref-type="bibr">110</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LIQUID PREPARATIONS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OTIC DROPS </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ciprofloxacin and dexamethasone suspension/drops</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benzalkonium chloride, boric acid, edetate disodium, acetic acid, sodium acetate, sodium chloride, sodium hydroxide, tyloxapol, water, hydrochloric acid, hydroxyethyl cellulose (3000 cps at 1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Ciprofloxacin hydrochloride</p></list-item><list-item><label>-</label><p>Dexamethasone</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Children from 6 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B111-pharmaceutics-13-00387" ref-type="bibr">111</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OPHTHALMIC DROPS OR COLLYRIUMS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ALLERGY EYE DROPS- ketotifen fumarate solution/ drops</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benzalkonium chloride 0.01%, glycerine, purified water. may contain hydrochloric acid and/or sodium<break/>hydroxide (to adjust PH).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ketotifen (0.025 %)<break/>(equivalent to ketotifen fumarate 0.035 %)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Children from 3 years.<break/>Children under 3 years of age: consult to doctor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B112-pharmaceutics-13-00387" ref-type="bibr">112</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NASAL DROPS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LITTLE REMEDIES DECONGESTANT NASAL DROPS<break/>phenylephrine hydrochloride liquid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benzalkonium chloride, glycerine, polyethylene glycol, potassium phosphate monobasic, purified water,<break/>Sodium EDTA, sodium phosphate dibasic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phenylephrine<break/>hydrochloride<break/>1.25 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Children</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B113-pharmaceutics-13-00387" ref-type="bibr">113</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ORAL DROPS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BIO-G-TUSS PAEDIATRIC DROPS (solution)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Citric acid, grape flavour, glycerine, methylparaben, polyethylene glycol, propylparaben, purified water,<break/>Sodium citrate, sucralose</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Dextromethorphan HBr (7.5 mg/mL)</p></list-item><list-item><label>-</label><p>Guaifenesin (88 mg/mL)</p></list-item><list-item><label>-</label><p>Phenylephrine HCl (2.5 mg/mL)</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Children</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B114-pharmaceutics-13-00387" ref-type="bibr">114</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SOLI PREPARATIONS</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CHEWABLE TABLET</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Children&#x02019;s Motrin&#x02014;Ibuprofen Tablet, Chewable</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acesulfame potassium, ammonium glycyrrhizin, aspartame, carnauba wax, croscarmellose sodium, hypromellose, magnesium stearate, mannitol, natural and artificial flavours, silicon dioxide, sodium lauryl sulphate, soybean oil, succinic acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ibuprofen 100 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 to 11 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B115-pharmaceutics-13-00387" ref-type="bibr">115</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acetaminophen Children&#x02019;s</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Citric acid, crospovidone, D&#x00026;C network No. 27 aluminium lake, D&#x00026;C network No. 30 aluminium lake, dextrates hydrated, ethyl cellulose, flavours, magnesium stearate, mannitol, polyethylene, stearic acid, sucralose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acetaminophen 80 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 to 6 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-pharmaceutics-13-00387" ref-type="bibr">116</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">TABLETS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diazepam Tablet </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anhydrous lactose, magnesium stearate, cellulose microcrystalline, FD&#x00026;C blue n. 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diazepam 10 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Children from 6 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B117-pharmaceutics-13-00387" ref-type="bibr">117</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dexamethasone 1.5 mg tablet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lactose monohydrate, magnesium stearate, maltodextrin, corn starch, sucrose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dexamethasone 1.5 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">It depends on the pathology</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B118-pharmaceutics-13-00387" ref-type="bibr">118</xref>]</td></tr></tbody></table></table-wrap></app><app id="app6-pharmaceutics-13-00387"><title>Appendix F</title><table-wrap id="pharmaceutics-13-00387-t0A5" orientation="portrait" position="anchor"><object-id pub-id-type="pii">pharmaceutics-13-00387-t0A5_Table A5</object-id><label>Table A5</label><caption><p>Liquid formulations for paediatric use in Research Articles.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Formula</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pharmaceutical Form</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Excipients</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Active Principle (Dose)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stability<break/>(Stability in Use)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Organic solvent-based formulation of lorazepam (Oral Solution)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG 400 (10% <italic>v/v</italic>), Propylene glycol (3% <italic>m/v</italic>), Glycerol (87% <italic>v/v</italic>) and Orange essence (0.1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lorazepam (1 mg/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Children 1 month to 12 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 months at 4 &#x000b0;C<break/>(Stability in use: 4 weeks)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B119-pharmaceutics-13-00387" ref-type="bibr">119</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution of amlodipine besylate for children</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sucrose jarabe (32% <italic>m/v</italic>), Methylparaben (solution 15% <italic>m/v</italic>) (0.3% <italic>m/v</italic>) and Purified water (75%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amlodipine Besylate (0.5 mg/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Population (children and teenagers)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 months at 4 &#x000b0;C<break/>(Stability in use: 18 weeks)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B120-pharmaceutics-13-00387" ref-type="bibr">120</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral tizanidine hydrochloride,<break/>Formulation for hospital use</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CMC (carboxymethyl cellulose) (0.5%), Potassic sorbate (0.15%), Sucralose (0.10%), Citric acid and Purified water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tizanidine Hydrochloride (1 g/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Population </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70 days at 15&#x02013;30 &#x000b0;C, 2&#x02013;8 &#x000b0;C and 40 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B121-pharmaceutics-13-00387" ref-type="bibr">121</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric oral formulation of clonidine hydrochloride</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sucrose syrup (20% <italic>v/v</italic>), Raspberry essence (0.05%), Methyl paraben solution 15% (1% <italic>m/v</italic>), Citric acid monohydrate (1% <italic>m/v</italic>), Disodium hydrogen phosphate (1.8% <italic>m/v</italic>) and Purified water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clonidine HCL (50 &#x000b5;g/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Population </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 months at room temperature, protected from light</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B122-pharmaceutics-13-00387" ref-type="bibr">122</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral liquid formulation of clonidine hydrochloride for paediatric patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Potassic sorbate, Sucrose and Monohydrate citric acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clonidine hydrochloride (20 &#x000b5;g/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Patients (all ages)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90 days at 5 &#x000b0;C (cooling) (Stability in use: 42 days at 5 &#x000b0;C)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B123-pharmaceutics-13-00387" ref-type="bibr">123</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric oral formulations of sodium dichloroacetate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vehicle Mascagni (% <italic>w/v</italic>): Sucralose (0.02%), Hydroxyethyl cellulose (0.2%), Citric acid (0.09%), Sodium citrate (0.09%) and Potassium sorbate (0.18%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium dichloroacetate (DCA) (9.5% <italic>w</italic>/<italic>v</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Patients </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 months at 4 &#x000b0;C and 25 &#x000b0;C (Stability in use: 1 month to 4 &#x000b0;C)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B124-pharmaceutics-13-00387" ref-type="bibr">124</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Furosemide solutions for personalized paediatric administration</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution (extemporaneous)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solution I: Buffer carbonate-bicarbonate (pH) (10 mL)<break/>Excipient for syrup (cps 100 mL) (ACOFARMA): sucrose, water, sorbitol, glycerine, aroma, citric acid, methyl paraben, potassium sorbate, sodium phosphate and colorant. <break/>Solution II: Buffer carbonate-bicarbonate (pH) (10 mL)<break/>-Excipient for syrup&#x02014;without sugars (cps 100 mL) (ACOFARMA): sodium saccharine, xanthan gum, water, sorbitol, glycerine, aroma, citric acid, sodium citrate, methyl paraben, propyl paraben, potassium sorbate, sodium phosphate and colorant. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Furosemide (2 mg/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatrics </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60 days at 4 and 25 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B125-pharmaceutics-13-00387" ref-type="bibr">125</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Formulation comprising acetaminophen, especially for paediatrics (PATENT)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral solution (nano-emulsion)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NF glyceryl mono linoleate (5&#x02013;30%, preferably 8-26% <italic>w/v</italic>), PEG-35 castor oil (30&#x02013;60%, preferably 39&#x02013;46% <italic>w/v</italic>), NF diethylene glycol mono ethyl ether (20&#x02013;45%, preferably 24&#x02013;40% <italic>w/v</italic>) and Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paracetamol (5&#x02013;18% <italic>w</italic>/<italic>v</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatrics </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B126-pharmaceutics-13-00387" ref-type="bibr">126</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric formulations of ursodeoxycholic acid from oral administration</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral suspension</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycerol (20%), Methyl cellulose 1000 (1% <italic>v/v</italic>) and Purified water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ursodeoxycholic acid (UDCA) (1.5 mg/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Population </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 days at 25 &#x000b0;C or in fridge</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B127-pharmaceutics-13-00387" ref-type="bibr">127</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral paediatric formulation of hydrochlorothiazide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral suspension</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycerol (20%), Methyl cellulose 1000 (1% <italic>v/v</italic>), Citric acid (pH corrector) and Water </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydrochlorothiazide (2 mg/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Population in general</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 weeks at 5 &#x000b0;C and protected from light</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B128-pharmaceutics-13-00387" ref-type="bibr">128</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral suspension of clindamycin HCL with ion exchange resin for paediatric use</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral suspension</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycerine (30% <italic>w/v</italic>), Sucralose (3%), Aroma of maple syrup (7%), Grape aroma (10%), Cremophor RH 40 (15%), Xanthan gum (0.2%) and Deionized water (cps 5 mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clindamycin HCL resin (Amberlite IRP 69) (5.5% <italic>w</italic>/<italic>v</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Population </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 month at 25 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B129-pharmaceutics-13-00387" ref-type="bibr">129</xref>,<xref rid="B130-pharmaceutics-13-00387" ref-type="bibr">130</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Isoniazid suspension formulated with cationic resin for paediatric use</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral suspension</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sorbitol solution 70% USP (4.9 mL/ 5 mL), USP monohydrate citric acid (50 mg/5 mL) and USP potassic sorbate (5 mg/5 mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Isoniazid resin/Kyron T-134<break/>100 mg/5 mL/200 mg/5 mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Population </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 months at 40 &#x000b0;C (accelerated stability study)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B131-pharmaceutics-13-00387" ref-type="bibr">131</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric xylometazoline nasal spray formulation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nasal Spray</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium colatum (105 mg/10 mL), PEG 400 (1.35 mL/10 mL), Sodium carboxy methyl cellulose (10 mg/10 mL), Glycerine (0.15 mL/10 mL), Methyl paraben (3.3 mg/10 mL), Sodium chloride and Purified water (cps 10 mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Xylometazoline HCl <break/>(5 mg/10 mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paediatric Population </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 months at 25 &#x000b0;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B132-pharmaceutics-13-00387" ref-type="bibr">132</xref>]</td></tr></tbody></table></table-wrap></app></app-group><ref-list><title>References</title><ref id="B1-pharmaceutics-13-00387"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ca&#x000f1;ete</surname><given-names>C.R.</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>M.P.</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>B.P.</given-names></name><name><surname>Caba&#x000f1;as</surname><given-names>M.J.P.</given-names></name></person-group><article-title>Formulaci&#x000f3;n magistral y excipientes en pediatr&#x000ed;a. El Farma-c&#x000e9;utico</article-title><source>Hospitales</source><year>2018</year><volume>213</volume><fpage>22</fpage><lpage>28</lpage></element-citation></ref><ref id="B2-pharmaceutics-13-00387"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salunke</surname><given-names>S.</given-names></name><name><surname>Brandys</surname><given-names>B.</given-names></name><name><surname>Giacoia</surname><given-names>G.</given-names></name><name><surname>Tuleu</surname><given-names>C.</given-names></name></person-group><article-title>The STEP (Safety and Toxicity of Excipients for Paediatrics) database: Part 2&#x02014;The pilot version</article-title><source>Int. J. Pharm.</source><year>2013</year><volume>457</volume><fpage>310</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2013.09.013</pub-id><?supplied-pmid 24070789?><pub-id pub-id-type="pmid">24070789</pub-id></element-citation></ref><ref id="B3-pharmaceutics-13-00387"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>G.</given-names></name></person-group><article-title>Safety of Excipients in Pediatric Formulations&#x02014;A Call for Toxicity Studies in Juvenile Animals?</article-title><source>Child</source><year>2015</year><volume>2</volume><fpage>191</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.3390/children2020191</pub-id><?supplied-pmid 27417358?><pub-id pub-id-type="pmid">27417358</pub-id></element-citation></ref><ref id="B4-pharmaceutics-13-00387"><label>4.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>European Medicines Agency (EMA)</collab><collab>Committee for Medicinal Products for Human Use (CHMP)</collab><collab>Paediatric Committee (PDCO)</collab></person-group><article-title>Guideline on Pharmaceutical Development of Medicines for Paediatric Use</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf">https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-06-01">(accessed on 1 June 2020)</date-in-citation></element-citation></ref><ref id="B5-pharmaceutics-13-00387"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunne</surname><given-names>J.</given-names></name></person-group><article-title>The European Regulation on medicines for paediatric use</article-title><source>Paediatr. Respir. Rev.</source><year>2007</year><volume>8</volume><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.prrv.2007.04.004</pub-id><pub-id pub-id-type="pmid">17574163</pub-id></element-citation></ref><ref id="B6-pharmaceutics-13-00387"><label>6.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group><article-title>European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/partners-networks/networks/european-network-paediatric-research-european-medicines-agency-enpr-ema">https://www.ema.europa.eu/en/partners-networks/networks/european-network-paediatric-research-european-medicines-agency-enpr-ema</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-06-01">(accessed on 1 June 2020)</date-in-citation></element-citation></ref><ref id="B7-pharmaceutics-13-00387"><label>7.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>EUR-Lex</collab></person-group><article-title>Regulation EC No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on Medicinal Products for Paediatric Use and Amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://eur-lex.europa.eu/eli/reg/2006/1901/oj">https://eur-lex.europa.eu/eli/reg/2006/1901/oj</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-01">(accessed on 1 July 2020)</date-in-citation></element-citation></ref><ref id="B8-pharmaceutics-13-00387"><label>8.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group><article-title>10-Year Report to the European Commission</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://ec.europa.eu/health/sites/health/files/files/paediatrics/2016_pc_report_2017/ema_10_year_report_for_consultation.pdf">https://ec.europa.eu/health/sites/health/files/files/paediatrics/2016_pc_report_2017/ema_10_year_report_for_consultation.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-06-02">(accessed on 2 June 2020)</date-in-citation></element-citation></ref><ref id="B9-pharmaceutics-13-00387"><label>9.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group><article-title>ICH E11(R1) Guideline on Clinical Investigation of Medicinal Products in the Pediatric Population. Step 5 [Internet]</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/ich-e11r1-step-5-guideline-clinical-investigation-medicinal-products-pediatric-population">https://www.ema.europa.eu/en/ich-e11r1-step-5-guideline-clinical-investigation-medicinal-products-pediatric-population</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-06-02">(accessed on 2 June 2020)</date-in-citation></element-citation></ref><ref id="B10-pharmaceutics-13-00387"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>M.</given-names></name><name><surname>Catapano</surname><given-names>M.</given-names></name><name><surname>Hirschfeld</surname><given-names>S.</given-names></name><name><surname>Giaquinto</surname><given-names>C.</given-names></name></person-group><article-title>Paediatric drug development: The impact of evolving regulations</article-title><source>Adv. Drug Deliv. Rev.</source><year>2014</year><volume>73</volume><fpage>2</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2014.02.003</pub-id><?supplied-pmid 24556465?><pub-id pub-id-type="pmid">24556465</pub-id></element-citation></ref><ref id="B11-pharmaceutics-13-00387"><label>11.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>WHO Library Cataloguing-in-Publication Data: WHO Model Formulary for Children 2010</collab></person-group><article-title>Based on the Second Model List of Essential Medicines for Children 2009</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/bookorders">http://www.who.int/bookorders</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-06-05">(accessed on 5 June 2020)</date-in-citation></element-citation></ref><ref id="B12-pharmaceutics-13-00387"><label>12.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>WHO World Health Organization</collab></person-group><article-title>Model List of Essential Medicines for Children</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/325772/WHO-MVP-EMP-IAU-2019.07-eng.pdf">https://apps.who.int/iris/bitstream/handle/10665/325772/WHO-MVP-EMP-IAU-2019.07-eng.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-06-06">(accessed on 6 June 2020)</date-in-citation></element-citation></ref><ref id="B13-pharmaceutics-13-00387"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daousani</surname><given-names>C.</given-names></name><name><surname>Karalis</surname><given-names>V.D.</given-names></name></person-group><article-title>Paediatric Medicines: Regulatory and Scientific Issues</article-title><source>Drug Res.</source><year>2017</year><volume>67</volume><fpage>377</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1055/s-0043-109788</pub-id><?supplied-pmid 28521373?><pub-id pub-id-type="pmid">28521373</pub-id></element-citation></ref><ref id="B14-pharmaceutics-13-00387"><label>14.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>FDA, Alyson Karesh MD</collab></person-group><article-title>Pediatric Drug Development: Regulatory Expectations</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/files/drugs/published/Pediatric-Drug-Development--Regulatory-Expectations.pdf">https://www.fda.gov/files/drugs/published/Pediatric-Drug-Development--Regulatory-Expectations.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-06-07">(accessed on 7 June 2020)</date-in-citation></element-citation></ref><ref id="B15-pharmaceutics-13-00387"><label>15.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>FDA</collab></person-group><article-title>Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-studies-safety-evaluation-pharmaceutical-excipients">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-studies-safety-evaluation-pharmaceutical-excipients</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-06-07">(accessed on 7 June 2020)</date-in-citation></element-citation></ref><ref id="B16-pharmaceutics-13-00387"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>J.</given-names></name><name><surname>Mills</surname><given-names>S.</given-names></name></person-group><article-title>Conference Report: Formulating Better Medicines for Children: 4th European Paediatric Formulation Initiative Conference</article-title><source>Ther. Deliv.</source><year>2013</year><volume>4</volume><fpage>21</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.4155/tde.12.135</pub-id><?supplied-pmid 23323778?><pub-id pub-id-type="pmid">23323778</pub-id></element-citation></ref><ref id="B17-pharmaceutics-13-00387"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christiansen</surname><given-names>N.</given-names></name></person-group><article-title>Ethanol exposure through medicines commonly used in paediatrics</article-title><source>Arch. Dis. Child. Educ. Pract.</source><year>2014</year><volume>100</volume><fpage>101</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2013-305671</pub-id></element-citation></ref><ref id="B18-pharmaceutics-13-00387"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuleu</surname><given-names>C.</given-names></name><name><surname>Breitkreutz</surname><given-names>J.</given-names></name></person-group><article-title>Educational Paper: Formulation-related issues in pediatric clinical pharmacology</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2012</year><volume>172</volume><fpage>717</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1007/s00431-012-1872-8</pub-id></element-citation></ref><ref id="B19-pharmaceutics-13-00387"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salunke</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Batchelor</surname><given-names>H.</given-names></name><name><surname>Walsh</surname><given-names>J.</given-names></name><name><surname>Turner</surname><given-names>R.</given-names></name><name><surname>Ju</surname><given-names>T.R.</given-names></name><name><surname>Tuleu</surname><given-names>C.</given-names></name><collab>on behalf of European Paediatric Formulation Initiative (EuPFI)</collab></person-group><article-title>European Paediatric Formulation Initiative (EuPFI)&#x02014;Formulating Ideas for Better Medicines for Children</article-title><source>AAPS PharmSciTech</source><year>2016</year><volume>18</volume><fpage>257</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1208/s12249-016-0584-1</pub-id><pub-id pub-id-type="pmid">27422653</pub-id></element-citation></ref><ref id="B20-pharmaceutics-13-00387"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Salunke</surname><given-names>S.</given-names></name></person-group><article-title>Development and Evaluation of Database of Safety and Toxicity of Excipients for Paediatrics (STEP Database)</article-title><source>Ph.D. Thesis</source><publisher-name>University College London</publisher-name><publisher-loc>London, UK</publisher-loc><year>2017</year><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://discovery.ucl.ac.uk/id/eprint/1546094/">https://discovery.ucl.ac.uk/id/eprint/1546094/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-20">(accessed on 20 July 2020)</date-in-citation></element-citation></ref><ref id="B21-pharmaceutics-13-00387"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salunke</surname><given-names>S.</given-names></name><name><surname>Tuleu</surname><given-names>C.</given-names></name></person-group><article-title>The STEP database through the end-users eyes&#x02014;USABILITY STUDY</article-title><source>Int. J. Pharm.</source><year>2015</year><volume>492</volume><fpage>316</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2015.06.016</pub-id><?supplied-pmid 26117188?><pub-id pub-id-type="pmid">26117188</pub-id></element-citation></ref><ref id="B22-pharmaceutics-13-00387"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salunke</surname><given-names>S.</given-names></name><name><surname>Giacoia</surname><given-names>G.</given-names></name><name><surname>Tuleu</surname><given-names>C.</given-names></name></person-group><article-title>The STEP (Safety and Toxicity of Excipients for Paediatrics) database. Part 1&#x02014;A need assessment study</article-title><source>Int. J. Pharm.</source><year>2012</year><volume>435</volume><fpage>101</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2012.05.004</pub-id><?supplied-pmid 22583848?><pub-id pub-id-type="pmid">22583848</pub-id></element-citation></ref><ref id="B23-pharmaceutics-13-00387"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonger</surname><given-names>G.C.</given-names></name><name><surname>Hakkinen</surname><given-names>P.</given-names></name><name><surname>Jordan</surname><given-names>S.</given-names></name><name><surname>Publicker</surname><given-names>S.</given-names></name></person-group><article-title>The National Library of Medicine&#x02019;s (NLM) Hazardous Substances Data Bank (HSDB): Background, recent enhancements and future plans</article-title><source>Toxicology</source><year>2014</year><volume>325</volume><fpage>209</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.tox.2014.09.003</pub-id><?supplied-pmid 25223694?><pub-id pub-id-type="pmid">25223694</pub-id></element-citation></ref><ref id="B24-pharmaceutics-13-00387"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valeur</surname><given-names>K.S.</given-names></name><name><surname>Hertel</surname><given-names>S.A.</given-names></name><name><surname>Lundstr&#x000f8;m</surname><given-names>K.E.</given-names></name><name><surname>Holst</surname><given-names>H.</given-names></name></person-group><article-title>Safe excipient exposure in neonates and small children&#x02014;Protocol for the SEEN project</article-title><source>Dan Med. J.</source><year>2017</year><volume>64</volume><fpage>A5324</fpage><pub-id pub-id-type="pmid">28157063</pub-id></element-citation></ref><ref id="B25-pharmaceutics-13-00387"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabiano</surname><given-names>V.</given-names></name><name><surname>Mameli</surname><given-names>C.</given-names></name><name><surname>Zuccotti</surname><given-names>G.V.</given-names></name></person-group><article-title>Paediatric pharmacology: Remember the excipients</article-title><source>Pharmacol. Res.</source><year>2011</year><volume>63</volume><fpage>362</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2011.01.006</pub-id><?supplied-pmid 21241804?><pub-id pub-id-type="pmid">21241804</pub-id></element-citation></ref><ref id="B26-pharmaceutics-13-00387"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soremekun</surname><given-names>R.</given-names></name><name><surname>Ogbuefi</surname><given-names>I.</given-names></name><name><surname>Aderemi-Williams</surname><given-names>R.</given-names></name></person-group><article-title>Prevalence of ethanol and other potentially harmful excipients in pediatric oral medicines: Survey of community pharmacies in a Nigerian City</article-title><source>BMC Res. Notes</source><year>2019</year><volume>12</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1186/s13104-019-4486-7</pub-id><pub-id pub-id-type="pmid">30602384</pub-id></element-citation></ref><ref id="B27-pharmaceutics-13-00387"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>L.A.</given-names></name><name><surname>Salunke</surname><given-names>S.</given-names></name><name><surname>Thompson</surname><given-names>K.</given-names></name><name><surname>Baer</surname><given-names>G.</given-names></name><name><surname>Fegley</surname><given-names>D.</given-names></name><name><surname>Turner</surname><given-names>M.A.</given-names></name></person-group><article-title>Challenges and strategies to facilitate formulation development of pediatric drug products: Safety qualification of excipients</article-title><source>Int. J. Pharm.</source><year>2018</year><volume>536</volume><fpage>563</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.07.042</pub-id><pub-id pub-id-type="pmid">28729174</pub-id></element-citation></ref><ref id="B28-pharmaceutics-13-00387"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parneli</surname><given-names>C.</given-names></name><name><surname>Srivari</surname><given-names>Y.</given-names></name><name><surname>Meiki</surname><given-names>Y.</given-names></name><name><surname>Mohammed</surname><given-names>A.</given-names></name><name><surname>Sri</surname><given-names>V.</given-names></name></person-group><article-title>Pharmaceutical excipients and paediatric formulations</article-title><source>Chem. Today</source><year>2012</year><volume>30</volume><fpage>56</fpage><lpage>61</lpage></element-citation></ref><ref id="B29-pharmaceutics-13-00387"><label>29.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Peir&#x000e9;</surname><given-names>M.A.G.</given-names></name></person-group><source>Farmacolog&#x000ed;a Pedi&#x000e1;trica</source><edition>1st ed.</edition><publisher-name>Ediciones Journal</publisher-name><publisher-loc>Ciudad Aut&#x000f3;noma de Buenos Aires, Argentina</publisher-loc><year>2019</year></element-citation></ref><ref id="B30-pharmaceutics-13-00387"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rowe</surname><given-names>R.C.</given-names></name><name><surname>Sheskey</surname><given-names>P.J.</given-names></name><name><surname>Owen</surname><given-names>S.C.</given-names></name></person-group><source>Handbook of Pharmaceutical Excipients</source><edition>6th ed.</edition><publisher-name>Pharmaceutical Press</publisher-name><publisher-loc>London, UK</publisher-loc><year>2006</year></element-citation></ref><ref id="B31-pharmaceutics-13-00387"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuccotti</surname><given-names>G.V.</given-names></name><name><surname>Fabiano</surname><given-names>V.</given-names></name></person-group><article-title>Safety issues with ethanol as an excipient in drugs intended for pediatric use</article-title><source>Expert Opin. Drug Saf.</source><year>2011</year><volume>10</volume><fpage>499</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1517/14740338.2011.565328</pub-id><?supplied-pmid 21417862?><pub-id pub-id-type="pmid">21417862</pub-id></element-citation></ref><ref id="B32-pharmaceutics-13-00387"><label>32.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>European Medicines Agency (EMA), Committee for Human Medicinal Products (CHMP)</collab></person-group><article-title>Questions and Answers on Ethanol in the Context of the Revision of the Guideline on &#x02018;Excipients in the Label and Package Leaflet of Medical Products for Human Use&#x02019; (CPMP/463/00)</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-ethanol-context-revision-guideline-excipients-label-package-leaflet-medicinal_en.pdf">https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-ethanol-context-revision-guideline-excipients-label-package-leaflet-medicinal_en.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-03-10">(accessed on 10 March 2020)</date-in-citation></element-citation></ref><ref id="B33-pharmaceutics-13-00387"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allegaert</surname><given-names>K.</given-names></name></person-group><article-title>Propylene Glycol in Neonates: Never Prescribed, Frequently Administered, Hardly Evaluated</article-title><source>J. Clin. Toxicol.</source><year>2012</year><volume>2</volume><fpage>113</fpage><pub-id pub-id-type="doi">10.4172/2161-0495.1000e113</pub-id></element-citation></ref><ref id="B34-pharmaceutics-13-00387"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allegaert</surname><given-names>K.</given-names></name><name><surname>Vanhaesebrouck</surname><given-names>S.</given-names></name><name><surname>Kulo</surname><given-names>A.</given-names></name><name><surname>Cosaert</surname><given-names>K.</given-names></name><name><surname>Verbesselt</surname><given-names>R.</given-names></name><name><surname>Debeer</surname><given-names>A.</given-names></name><name><surname>De Hoon</surname><given-names>J.</given-names></name></person-group><article-title>Prospective assessment of short-term propylene glycol tolerance in neonates</article-title><source>Arch. Dis. Child.</source><year>2010</year><volume>95</volume><fpage>1054</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1136/adc.2010.190330</pub-id><pub-id pub-id-type="pmid">20959360</pub-id></element-citation></ref><ref id="B35-pharmaceutics-13-00387"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hidalgo</surname><given-names>M.E.P.</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>B.N.</given-names></name></person-group><article-title>Formas Farmac&#x000e9;uticas L&#x000ed;quidas Orales (II): Excipientes</article-title><source>Panor. Actual Medicam.</source><year>2016</year><volume>40</volume><fpage>842</fpage><lpage>848</lpage><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://dialnet.unirioja.es/servlet/articulo?codigo=5685059">https://dialnet.unirioja.es/servlet/articulo?codigo=5685059</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-05-20">(accessed on 20 May 2020)</date-in-citation></element-citation></ref><ref id="B36-pharmaceutics-13-00387"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nellis</surname><given-names>G.</given-names></name><name><surname>Metsvaht</surname><given-names>T.</given-names></name><name><surname>Varendi</surname><given-names>H.</given-names></name><name><surname>Toompere</surname><given-names>K.</given-names></name><name><surname>Lass</surname><given-names>J.</given-names></name><name><surname>Mesek</surname><given-names>I.</given-names></name><name><surname>Nunn</surname><given-names>A.J.</given-names></name><name><surname>A Turner</surname><given-names>M.</given-names></name><name><surname>Lutsar</surname><given-names>I.</given-names></name></person-group><article-title>Potentially harmful excipients in neonatal medicines: A pan-European observational study</article-title><source>Arch. Dis. Child.</source><year>2015</year><volume>100</volume><fpage>694</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2014-307793</pub-id><pub-id pub-id-type="pmid">25854872</pub-id></element-citation></ref><ref id="B37-pharmaceutics-13-00387"><label>37.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Nellis</surname><given-names>G.</given-names></name></person-group><article-title>The Use of Excipients in Medicines Administered to Neonates in Europe</article-title><source>Ph.D. Thesis</source><publisher-name>University of Tartu</publisher-name><publisher-loc>Tartu, Estonia</publisher-loc><year>2017</year><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://rahvatervis.ut.ee/handle/1/6757">http://rahvatervis.ut.ee/handle/1/6757</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-05-03">(accessed on 3 May 2020)</date-in-citation></element-citation></ref><ref id="B38-pharmaceutics-13-00387"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>S.</given-names></name><name><surname>Turner</surname><given-names>M.</given-names></name></person-group><article-title>European Study of Neonatal Exposure to Excipients (ESNEE)</article-title><source>Infant</source><year>2011</year><volume>7</volume><fpage>196</fpage><lpage>199</lpage><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.infantjournal.co.uk/pdf/inf_042_ien.pdf">http://www.infantjournal.co.uk/pdf/inf_042_ien.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-05-03">(accessed on 3 May 2020)</date-in-citation></element-citation></ref><ref id="B39-pharmaceutics-13-00387"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nahata</surname><given-names>M.C.</given-names></name></person-group><article-title>Safety of &#x0201c;inert&#x0201d; additives or excipients in paediatric medicines</article-title><source>Arch. Dis. Child. Fetal Neonatal Ed.</source><year>2009</year><volume>94</volume><fpage>F392</fpage><lpage>F393</lpage><pub-id pub-id-type="doi">10.1136/adc.2009.160192</pub-id><pub-id pub-id-type="pmid">19846397</pub-id></element-citation></ref><ref id="B40-pharmaceutics-13-00387"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whittaker</surname><given-names>A.</given-names></name><name><surname>Currie</surname><given-names>A.E.</given-names></name><name><surname>Turner</surname><given-names>M.A.</given-names></name><name><surname>Field</surname><given-names>D.J.</given-names></name><name><surname>Mulla</surname><given-names>H.</given-names></name><name><surname>Pandya</surname><given-names>H.C.</given-names></name></person-group><article-title>Toxic additives in medication for pre-term infants</article-title><source>Arch. Dis. Child. Fetal Neonatal Ed.</source><year>2009</year><volume>94</volume><fpage>236</fpage><lpage>240</lpage><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://fn.bmj.com/content/94/4/F236">https://fn.bmj.com/content/94/4/F236</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-05-20">(accessed on 20 May 2020)</date-in-citation><pub-id pub-id-type="doi">10.1136/adc.2008.146035</pub-id></element-citation></ref><ref id="B41-pharmaceutics-13-00387"><label>41.</label><element-citation publication-type="journal"><article-title>Committee on Drugs "Inactive" Ingredients in Pharmaceutical Products: Update (Subject Review)</article-title><source>Pediatry</source><year>1997</year><volume>99</volume><fpage>268</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1542/peds.99.2.268</pub-id><?supplied-pmid 9024461?><pub-id pub-id-type="pmid">9024461</pub-id></element-citation></ref><ref id="B42-pharmaceutics-13-00387"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fister</surname><given-names>P.</given-names></name><name><surname>Urh</surname><given-names>S.</given-names></name><name><surname>Karner</surname><given-names>A.</given-names></name><name><surname>Krzan</surname><given-names>M.</given-names></name><name><surname>Paro-Panjan</surname><given-names>D.</given-names></name></person-group><article-title>The prevalence and pattern of pharmaceutical and excipient exposure in a neonatal unit in Slovenia</article-title><source>J. Matern. Neonatal Med.</source><year>2015</year><volume>28</volume><fpage>2053</fpage><lpage>2061</lpage><pub-id pub-id-type="doi">10.3109/14767058.2014.976549</pub-id><?supplied-pmid 25316561?><pub-id pub-id-type="pmid">25316561</pub-id></element-citation></ref><ref id="B43-pharmaceutics-13-00387"><label>43.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>Committee for Medicinal Products for Human Use (CHMP)</collab></person-group><article-title>Reflection Paper: Formulations of Choice for the Paediatric Population Agreed by Paediatric Working Party &#x00026; Quality Working Party Adoption by Chmp for Release for Consultation End of Consultation (Deadline for Comments)</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/formulations-choice-paediatric-population">https://www.ema.europa.eu/en/formulations-choice-paediatric-population</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-03-20">(accessed on 20 March 2020)</date-in-citation></element-citation></ref><ref id="B44-pharmaceutics-13-00387"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valeur</surname><given-names>K.S.</given-names></name><name><surname>Holst</surname><given-names>H.</given-names></name><name><surname>Allegaert</surname><given-names>K.</given-names></name></person-group><article-title>Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered</article-title><source>Pharm. Med.</source><year>2018</year><volume>32</volume><fpage>251</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1007/s40290-018-0243-9</pub-id><?supplied-pmid 30174435?><pub-id pub-id-type="pmid">30174435</pub-id></element-citation></ref><ref id="B45-pharmaceutics-13-00387"><label>45.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Faul&#x000ed;</surname><given-names>T.C.</given-names></name></person-group><source>Tratado de Farmacia Galenica.</source><edition>1st ed.</edition><publisher-name>Luz&#x000e1;n 5, S.A. de Ediciones</publisher-name><publisher-loc>Madrid, Spain</publisher-loc><year>1993</year></element-citation></ref><ref id="B46-pharmaceutics-13-00387"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vally</surname><given-names>H.</given-names></name><name><surname>La Misso</surname><given-names>N.</given-names></name></person-group><article-title>Adverse reactions to the sulphite additives</article-title><source>Gastroenterol. Hepatol. Bed Bench</source><year>2012</year><volume>5</volume><fpage>16</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">24834193</pub-id></element-citation></ref><ref id="B47-pharmaceutics-13-00387"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duro</surname><given-names>D.</given-names></name><name><surname>Rising</surname><given-names>R.</given-names></name><name><surname>Cedillo</surname><given-names>M.</given-names></name><name><surname>Lifshitz</surname><given-names>F.</given-names></name></person-group><article-title>Association between infantile colic and carbohydrate malabsorption from fruit juices in infancy</article-title><source>Pediatry</source><year>2002</year><volume>109</volume><fpage>797</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1542/peds.109.5.797</pub-id></element-citation></ref><ref id="B48-pharmaceutics-13-00387"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakama</surname><given-names>K.</given-names></name><name><surname>Dos Santos</surname><given-names>R.</given-names></name><name><surname>Serpa</surname><given-names>P.</given-names></name><name><surname>Maciel</surname><given-names>T.</given-names></name><name><surname>Haas</surname><given-names>S.</given-names></name></person-group><article-title>Organoleptic excipients used in pediatric antibiotics</article-title><source>Arch. P&#x000e9;diatrie</source><year>2019</year><volume>26</volume><fpage>431</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1016/j.arcped.2019.09.008</pub-id></element-citation></ref><ref id="B49-pharmaceutics-13-00387"><label>49.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pun&#x000ed;n</surname><given-names>E.C.</given-names></name><name><surname>Ballester</surname><given-names>A.V.</given-names></name><name><surname>D&#x000e1;vila</surname><given-names>C.P.</given-names></name><name><surname>Varela</surname><given-names>J.J.C.</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>M.J.O.</given-names></name><name><surname>Arias</surname><given-names>J.D.</given-names></name><name><surname>Segado</surname><given-names>M.I.J.</given-names></name><name><surname>Herrero</surname><given-names>L.P.</given-names></name><name><surname>Fortes</surname><given-names>S.G.</given-names></name><name><surname>Pi&#x000f1;eiro</surname><given-names>G.C.</given-names></name><etal/></person-group><source>Aspectos Pr&#x000e1;cticos de la Farmacotecnia en un Servicio de Farmacia. Situaci&#x000f3;n Actual [Online]</source><person-group person-group-type="editor"><name><surname>Pi&#x000f1;eiro</surname><given-names>G.C.</given-names></name></person-group><publisher-name>Master Line &#x00026; Prodigio S.L.</publisher-name><publisher-loc>Madrid, Spain</publisher-loc><year>2011</year><comment>Available online: <ext-link ext-link-type="uri" xlink:href="www.sefh.es/bibliotecavirtual/FARMACOTECNIA/AspectosPracticos.pdf">www.sefh.es/bibliotecavirtual/FARMACOTECNIA/AspectosPracticos.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-13">(accessed on 13 October 2020)</date-in-citation></element-citation></ref><ref id="B50-pharmaceutics-13-00387"><label>50.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>Euskadi.eus</collab></person-group><article-title>Bolet&#x000ed;n INFAC. A&#x000f1;o 2019. Volumen 27. N&#x000ba; 3- Excipientes: &#x000bf;Sustancias Inertes?</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.euskadi.eus/boletin-infac-ano-2019-volumen-27/web01-a2cevime/es/">https://www.euskadi.eus/boletin-infac-ano-2019-volumen-27/web01-a2cevime/es/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-13">(accessed on 13 October 2020)</date-in-citation></element-citation></ref><ref id="B51-pharmaceutics-13-00387"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gryczke</surname><given-names>A.</given-names></name><name><surname>Schminke</surname><given-names>S.</given-names></name><name><surname>Maniruzzaman</surname><given-names>M.</given-names></name><name><surname>Beck</surname><given-names>J.</given-names></name><name><surname>Douroumis</surname><given-names>D.</given-names></name></person-group><article-title>Development and evaluation of orally disintegrating tablets (ODTs) containing Ibuprofen granules prepared by hot melt extrusion</article-title><source>Colloids Surf. B Biointerfaces</source><year>2011</year><volume>86</volume><fpage>275</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2011.04.007</pub-id><?supplied-pmid 21592751?><pub-id pub-id-type="pmid">21592751</pub-id></element-citation></ref><ref id="B52-pharmaceutics-13-00387"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pahwa</surname><given-names>R.</given-names></name><name><surname>Piplani</surname><given-names>M.</given-names></name><name><surname>Sharma</surname><given-names>P.C.</given-names></name><name><surname>Kaushik</surname><given-names>D.</given-names></name><name><surname>Nanda</surname><given-names>S.</given-names></name></person-group><article-title>Orally Disintegrating Tablets&#x02014;Friendly to Pediatrics and Geriatrics</article-title><source>Arch. Appl. Sci. Res.</source><year>2010</year><volume>2</volume><fpage>35</fpage><lpage>48</lpage><comment>Available online: <ext-link ext-link-type="uri" xlink:href="www.scholarsresearchlibrary.com/articles/orally-disintegrating-tablets--friendly-to-pediatrics-and-geriatrics.pdf">www.scholarsresearchlibrary.com/articles/orally-disintegrating-tablets--friendly-to-pediatrics-and-geriatrics.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-11-14">(accessed on 14 November 2020)</date-in-citation></element-citation></ref><ref id="B53-pharmaceutics-13-00387"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar-D&#x000ed;az</surname><given-names>J.E.</given-names></name><name><surname>Garc&#x000ed;a-Montoya</surname><given-names>E.</given-names></name><name><surname>Su&#x000f1;e-Negre</surname><given-names>J.M.</given-names></name><name><surname>P&#x000e9;rez-Lozano</surname><given-names>P.</given-names></name><name><surname>Mi&#x000f1;arro</surname><given-names>M.</given-names></name><name><surname>Tic&#x000f3;</surname><given-names>J.R.</given-names></name></person-group><article-title>Predicting orally disintegrating tablets formulations of ibuprophen tablets: An application of the new SeDeM-ODT expert system</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2012</year><volume>80</volume><fpage>638</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2011.12.012</pub-id><pub-id pub-id-type="pmid">22245156</pub-id></element-citation></ref><ref id="B54-pharmaceutics-13-00387"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arvapalli</surname><given-names>S.</given-names></name><name><surname>Swamy</surname><given-names>D.</given-names></name><collab>Shyamala</collab></person-group><article-title>Oral Disintegration Tablets: An Updated Review</article-title><source>IAJPS</source><year>2019</year><volume>6</volume><fpage>6926</fpage><lpage>6934</lpage><pub-id pub-id-type="doi">10.5281/zenodo.2617331</pub-id></element-citation></ref><ref id="B55-pharmaceutics-13-00387"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrada-Manch&#x000f3;n</surname><given-names>H.</given-names></name><name><surname>Rodr&#x000ed;guez-Gonz&#x000e1;lez</surname><given-names>D.</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>M.A.</given-names></name><name><surname>Su&#x000f1;&#x000e9;-Pou</surname><given-names>M.</given-names></name><name><surname>P&#x000e9;rez-Lozano</surname><given-names>P.</given-names></name><name><surname>Garc&#x000ed;a-Montoya</surname><given-names>E.</given-names></name><name><surname>Aguilar</surname><given-names>E.</given-names></name></person-group><article-title>3D printed gummies: Personalized drug dosage in a safe and appealing way</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>587</volume><fpage>119687</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119687</pub-id><?supplied-pmid 32730802?><pub-id pub-id-type="pmid">32730802</pub-id></element-citation></ref><ref id="B56-pharmaceutics-13-00387"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kriegel</surname><given-names>C.</given-names></name><name><surname>Festag</surname><given-names>M.</given-names></name><name><surname>Kishore</surname><given-names>R.S.</given-names></name><name><surname>Roethlisberger</surname><given-names>D.</given-names></name><name><surname>Schmitt</surname><given-names>G.</given-names></name></person-group><article-title>Pediatric Safety of Polysorbates in Drug Formulations</article-title><source>Children</source><year>2019</year><volume>7</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.3390/children7010001</pub-id></element-citation></ref><ref id="B57-pharmaceutics-13-00387"><label>57.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Amoxicilina Normon 250 mg/5 mL Polvo para Suspensi&#x000f3;n Oral EFG.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/63354/FT_63354.html">https://cima.aemps.es/cima/dochtml/ft/63354/FT_63354.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-01">(accessed on 1 July 2020)</date-in-citation></element-citation></ref><ref id="B58-pharmaceutics-13-00387"><label>58.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Azitromicina Sandoz 200 mg/5 mL Polvo para Suspensi&#x000f3;n Oral EFG.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/71180/FT_71180.html#6-datos-farmac-uticos">https://cima.aemps.es/cima/dochtml/ft/71180/FT_71180.html#6-datos-farmac-uticos</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-01">(accessed on 1 July 2020)</date-in-citation></element-citation></ref><ref id="B59-pharmaceutics-13-00387"><label>59.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Gelocatil Pedi&#x000e1;trico 325 mg Granulado.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/72343/FT_72343.html#6-datos-farmac-uticos">https://cima.aemps.es/cima/dochtml/ft/72343/FT_72343.html#6-datos-farmac-uticos</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-01">(accessed on 1 July 2020)</date-in-citation></element-citation></ref><ref id="B60-pharmaceutics-13-00387"><label>60.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Apiretal 325 mg Comprimidos Bucodispersables.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/70571/FT_70571.html#6-datos-farmac-uticos">https://cima.aemps.es/cima/dochtml/ft/70571/FT_70571.html#6-datos-farmac-uticos</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-01">(accessed on 1 July 2020)</date-in-citation></element-citation></ref><ref id="B61-pharmaceutics-13-00387"><label>61.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Junifen 200 mg Comprimidos Bucodispersables Sabor Lim&#x000f3;n.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/64966/FT_64966.html#6-datos-farmac-uticos">https://cima.aemps.es/cima/dochtml/ft/64966/FT_64966.html#6-datos-farmac-uticos</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-05">(accessed on 5 July 2020)</date-in-citation></element-citation></ref><ref id="B62-pharmaceutics-13-00387"><label>62.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Febrectal Lactantes 150 mg Supositorios</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/45930/FT_45930.html#6-datos-farmac-uticos">https://cima.aemps.es/cima/dochtml/ft/45930/FT_45930.html#6-datos-farmac-uticos</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-05">(accessed on 5 July 2020)</date-in-citation></element-citation></ref><ref id="B63-pharmaceutics-13-00387"><label>63.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Fenistil 1 mg/g Gel.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/54083/FT_54083.html">https://cima.aemps.es/cima/dochtml/ft/54083/FT_54083.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-09">(accessed on 9 July 2020)</date-in-citation></element-citation></ref><ref id="B64-pharmaceutics-13-00387"><label>64.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Perme-Cure 5 % Crema.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/pdfs/ft/64052/FT_64052.pdf">https://cima.aemps.es/cima/pdfs/ft/64052/FT_64052.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-09">(accessed on 9 July 2020)</date-in-citation></element-citation></ref><ref id="B65-pharmaceutics-13-00387"><label>65.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Oftacilox 3 mg/g Pomada Oft&#x000e1;lmica.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/64904/FT_64904.html#1-nombre-del-medicamento">https://cima.aemps.es/cima/dochtml/ft/64904/FT_64904.html#1-nombre-del-medicamento</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-09">(accessed on 9 July 2020)</date-in-citation></element-citation></ref><ref id="B66-pharmaceutics-13-00387"><label>66.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Anticongestiva Cus&#x000ed; (Pasta Lassar).</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/33302/FT_33302.html#6-datos-farmac-uticos">https://cima.aemps.es/cima/dochtml/ft/33302/FT_33302.html#6-datos-farmac-uticos</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-09">(accessed on 9 July 2020)</date-in-citation></element-citation></ref><ref id="B67-pharmaceutics-13-00387"><label>67.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Lactisona 10 mg/mL Emulsi&#x000f3;n Cut&#x000e1;nea. Ficha T&#x000e9;cnica.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/59709/FichaTecnica_59709.html">https://cima.aemps.es/cima/dochtml/ft/59709/FichaTecnica_59709.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-09">(accessed on 9 July 2020)</date-in-citation></element-citation></ref><ref id="B68-pharmaceutics-13-00387"><label>68.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Eichholtz</surname><given-names>F.</given-names></name></person-group><source>Tratado de Farmacolog&#x000ed;a</source><edition>1st ed.</edition><publisher-name>Editorial Aguilar</publisher-name><publisher-loc>Madrid, Spain</publisher-loc><year>1961</year></element-citation></ref><ref id="B69-pharmaceutics-13-00387"><label>69.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>ACCORD</collab></person-group><article-title>Diazepam 2 mg/5 mL Oral Solution Sugar Free</article-title><source>Package Leaflet: Information for the Patient.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.medicines.org.uk/emc/product/5783/pil">https://www.medicines.org.uk/emc/product/5783/pil</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-03">(accessed on 3 August 2020)</date-in-citation></element-citation></ref><ref id="B70-pharmaceutics-13-00387"><label>70.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Paracetamol Level 100 mg/mL Soluci&#x000f3;n Oral EFG.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/68318/FT_68318.html">https://cima.aemps.es/cima/dochtml/ft/68318/FT_68318.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-03">(accessed on 3 August 2020)</date-in-citation></element-citation></ref><ref id="B71-pharmaceutics-13-00387"><label>71.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>RxList</collab></person-group><article-title>Diazepam Intensol</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.rxlist.com/diazepam-intensol-drug.htm#side_effects">https://www.rxlist.com/diazepam-intensol-drug.htm#side_effects</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-03">(accessed on 3 August 2020)</date-in-citation></element-citation></ref><ref id="B72-pharmaceutics-13-00387"><label>72.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>Focus Pharmaceuticals Ltd</collab></person-group><article-title>Prednisolone 10 mg/mL Oral Solution</article-title><source>Package Leaflet: Information for the User.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.medicines.org.uk/emc/product/3370/smpc">https://www.medicines.org.uk/emc/product/3370/smpc</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-03">(accessed on 3 August 2020)</date-in-citation></element-citation></ref><ref id="B73-pharmaceutics-13-00387"><label>73.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>PRIMEX PHARMACEUTICALS</collab></person-group><article-title>Ozalin&#x000ae; 2 mg/mL. Package Leaflet: Information for the User</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://mri.cts-mrp.eu/Human/Downloads/FR_H_0610_001_FinalPL.pdf">https://mri.cts-mrp.eu/Human/Downloads/FR_H_0610_001_FinalPL.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-04">(accessed on 4 August 2020)</date-in-citation></element-citation></ref><ref id="B74-pharmaceutics-13-00387"><label>74.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Flumil 20 mg/mL Soluci&#x000f3;n Oral.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/63512/FT_63512.html">https://cima.aemps.es/cima/dochtml/ft/63512/FT_63512.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-05">(accessed on 5 August 2020)</date-in-citation></element-citation></ref><ref id="B75-pharmaceutics-13-00387"><label>75.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Lanacordin Pedi&#x000e1;trico 0.05 mg/mL Soluci&#x000f3;n Oral.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/34755/FichaTecnica_34755.html">https://cima.aemps.es/cima/dochtml/ft/34755/FichaTecnica_34755.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-05">(accessed on 5 August 2020)</date-in-citation></element-citation></ref><ref id="B76-pharmaceutics-13-00387"><label>76.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>Rosemont Pharmaceuticals Limited</collab></person-group><article-title>Paracetamol 120 mg/5 mL Oral Suspension</article-title><source>Package Leaflet: Information for the User.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.medicines.org.uk/emc/product/6693/smpc">https://www.medicines.org.uk/emc/product/6693/smpc</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-07">(accessed on 7 August 2020)</date-in-citation></element-citation></ref><ref id="B77-pharmaceutics-13-00387"><label>77.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>Pinewood Laboratories Limited</collab></person-group><article-title>Junior Parapaed 120 mg/5 mL Oral Suspension</article-title><source>Patient Information Leaflet.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.hpra.ie/img/uploaded/swedocuments/bf1ca653-1934-4daa-8632-f76ebef7c70c.pdf">https://www.hpra.ie/img/uploaded/swedocuments/bf1ca653-1934-4daa-8632-f76ebef7c70c.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-07">(accessed on 7 August 2020)</date-in-citation></element-citation></ref><ref id="B78-pharmaceutics-13-00387"><label>78.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Mycostatin 100,000 UI/mL Suspensi&#x000f3;n Oral.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/28262/FichaTecnica_28262.html">https://cima.aemps.es/cima/dochtml/ft/28262/FichaTecnica_28262.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-07">(accessed on 7 August 2020)</date-in-citation></element-citation></ref><ref id="B79-pharmaceutics-13-00387"><label>79.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Algidrin Pediatrico 20 mg/mL Suspensi&#x000f3;n Oral.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/78859/FichaTecnica_78859.html">https://cima.aemps.es/cima/dochtml/ft/78859/FichaTecnica_78859.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-08">(accessed on 8 August 2020)</date-in-citation></element-citation></ref><ref id="B80-pharmaceutics-13-00387"><label>80.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Septrin Pediatrico 8 mg/40 mg/mL Suspension Oral.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/pdfs/es/ft/48671/48671_ft.pdf">https://cima.aemps.es/cima/pdfs/es/ft/48671/48671_ft.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-08">(accessed on 8 August 2020)</date-in-citation></element-citation></ref><ref id="B81-pharmaceutics-13-00387"><label>81.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>Pinewood Laboratories Limited</collab></person-group><article-title>Patient Information Leaflet: Paediatric Paracetamol Elixir BP Paracetamol 120 mg/5 mL</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.drugs.com/uk/paediatric-paracetamol-elixir-bp-leaflet.html">https://www.drugs.com/uk/paediatric-paracetamol-elixir-bp-leaflet.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-09">(accessed on 9 August 2020)</date-in-citation></element-citation></ref><ref id="B82-pharmaceutics-13-00387"><label>82.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>Aspen Pharma</collab></person-group><article-title>Lanoxin Pg Elixir</article-title><source>Package Leaflet: Information for the User.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.medicines.org.uk/emc/product/5463/smpc">https://www.medicines.org.uk/emc/product/5463/smpc</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-10">(accessed on 10 August 2020)</date-in-citation></element-citation></ref><ref id="B83-pharmaceutics-13-00387"><label>83.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>Medicine-Online</collab></person-group><article-title>Daleron Syrup 120 mg/5 mL. 100 mL</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.medicine-online.org/en/quality-products/2483-daleron-syrup-120-mg-5-ml-100-ml-.html">https://www.medicine-online.org/en/quality-products/2483-daleron-syrup-120-mg-5-ml-100-ml-.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-10">(accessed on 10 August 2020)</date-in-citation></element-citation></ref><ref id="B84-pharmaceutics-13-00387"><label>84.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>Pinewood Healthcare</collab></person-group><article-title>Loratadine 5 mg/5 mL Syrup</article-title><source>Patient Information Leaflet.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.medicines.org.uk/emc/product/4567/smpc">https://www.medicines.org.uk/emc/product/4567/smpc</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-11">(accessed on 11 August 2020)</date-in-citation></element-citation></ref><ref id="B85-pharmaceutics-13-00387"><label>85.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Polaramine 0.4 mg/mL Jarabe.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/32801/FichaTecnica_32801.html">https://cima.aemps.es/cima/dochtml/ft/32801/FichaTecnica_32801.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-11">(accessed on 11 August 2020)</date-in-citation></element-citation></ref><ref id="B86-pharmaceutics-13-00387"><label>86.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Mucosan Pedi&#x000e1;trico 3 mg/mL Jarabe.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/56156/FT_56156.html">https://cima.aemps.es/cima/dochtml/ft/56156/FT_56156.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-11">(accessed on 11 August 2020)</date-in-citation></element-citation></ref><ref id="B87-pharmaceutics-13-00387"><label>87.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Romilar 15 mg/mL Gotas Orales en Soluci&#x000f3;n.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/24379/FT_24379.html">https://cima.aemps.es/cima/dochtml/ft/24379/FT_24379.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-12">(accessed on 12 August 2020)</date-in-citation></element-citation></ref><ref id="B88-pharmaceutics-13-00387"><label>88.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Alerlisin 10 mg/mL Gotas Orales en Soluci&#x000f3;n.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/62788/FT_62788.html">https://cima.aemps.es/cima/dochtml/ft/62788/FT_62788.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-12">(accessed on 12 August 2020)</date-in-citation></element-citation></ref><ref id="B89-pharmaceutics-13-00387"><label>89.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Fiche T&#x000e9;cnica Cleboril Pedi&#x000e1;trico 62.5 &#x000b5;g Gotas Orales en Soluci&#x000f3;n.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/56657/FichaTecnica_56657.html">https://cima.aemps.es/cima/dochtml/ft/56657/FichaTecnica_56657.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-12">(accessed on 12 August 2020)</date-in-citation></element-citation></ref><ref id="B90-pharmaceutics-13-00387"><label>90.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Fluor Lacer 1.4 mg/mL Gotas Orales.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/57746/FT_57746.html">https://cima.aemps.es/cima/dochtml/ft/57746/FT_57746.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-13">(accessed on 13 August 2020)</date-in-citation></element-citation></ref><ref id="B91-pharmaceutics-13-00387"><label>91.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Fiche T&#x000e9;cnica Hidropolivit Gotas Orales en Soluci&#x000f3;n.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/44000/FT_44000.html">https://cima.aemps.es/cima/dochtml/ft/44000/FT_44000.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-13">(accessed on 13 August 2020)</date-in-citation></element-citation></ref><ref id="B92-pharmaceutics-13-00387"><label>92.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Fiche T&#x000e9;cnica Largactil 40 mg/mL Gotas Orales en Soluci&#x000f3;n.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/23661/FichaTecnica_23661.html">https://cima.aemps.es/cima/dochtml/ft/23661/FichaTecnica_23661.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-13">(accessed on 13 August 2020)</date-in-citation></element-citation></ref><ref id="B93-pharmaceutics-13-00387"><label>93.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Nemactil 40 mg/mL Gotas Orales en Soluci&#x000f3;n.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/41573/FT_41573.html">https://cima.aemps.es/cima/dochtml/ft/41573/FT_41573.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-14">(accessed on 14 August 2020)</date-in-citation></element-citation></ref><ref id="B94-pharmaceutics-13-00387"><label>94.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Fiche T&#x000e9;cnica Zamene 22.75 mg/mL Gotas Orales en Suspensi&#x000f3;n.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/61050/FT_61050.html">https://cima.aemps.es/cima/dochtml/ft/61050/FT_61050.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-14">(accessed on 14 August 2020)</date-in-citation></element-citation></ref><ref id="B95-pharmaceutics-13-00387"><label>95.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Fiche T&#x000e9;cnica Dezacor 22.75 mg/mL Gotas Orales en Suspensi&#x000f3;n.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/61049/FT_61049.html">https://cima.aemps.es/cima/dochtml/ft/61049/FT_61049.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-14">(accessed on 14 August 2020)</date-in-citation></element-citation></ref><ref id="B96-pharmaceutics-13-00387"><label>96.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>EMC (ELECTRONIC MEDICINES COMPENDIUM)</collab></person-group><article-title>Atropine Eye Drops BP 1.0% w/v Vistatropine Eye Drops 1.0% w/v</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.medicines.org.uk/emc/medicine/29117">https://www.medicines.org.uk/emc/medicine/29117</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-24">(accessed on 24 August 2020)</date-in-citation></element-citation></ref><ref id="B97-pharmaceutics-13-00387"><label>97.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Fiche T&#x000e9;cnica Chibroxin 3 mg/ml Colirio en Soluci&#x000f3;n.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/59248/FichaTecnica_59248.html">https://cima.aemps.es/cima/dochtml/ft/59248/FichaTecnica_59248.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-24">(accessed on 24 August 2020)</date-in-citation></element-citation></ref><ref id="B98-pharmaceutics-13-00387"><label>98.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Fiche T&#x000e9;cnica Rhinov&#x000ed;n&#x000ae; Infantil 0.5 mg/mL Gotas Nasales en Soluci&#x000f3;n.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/37037/FT_37037.html">https://cima.aemps.es/cima/dochtml/ft/37037/FT_37037.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-24">(accessed on 24 August 2020)</date-in-citation></element-citation></ref><ref id="B99-pharmaceutics-13-00387"><label>99.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Ficha T&#x000e9;cnica Utabon Ni&#x000f1;os 0.25 mg/mL Gotas Nasales en Soluci&#x000f3;n.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/46065/FT_46065.html">https://cima.aemps.es/cima/dochtml/ft/46065/FT_46065.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-25">(accessed on 25 August 2020)</date-in-citation></element-citation></ref><ref id="B100-pharmaceutics-13-00387"><label>100.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Fiche T&#x000e9;cnica Cetraxal &#x000d3;tico 3 mg/mL Gotas &#x000d3;ticas en Soluci&#x000f3;n.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/60883/FT_60883.html">https://cima.aemps.es/cima/dochtml/ft/60883/FT_60883.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-25">(accessed on 25 August 2020)</date-in-citation></element-citation></ref><ref id="B101-pharmaceutics-13-00387"><label>101.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Fiche T&#x000e9;cnica Otix Gotas &#x000d3;ticas en Soluci&#x000f3;n.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/59381/FT_59381.html">https://cima.aemps.es/cima/dochtml/ft/59381/FT_59381.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-25">(accessed on 25 August 2020)</date-in-citation></element-citation></ref><ref id="B102-pharmaceutics-13-00387"><label>102.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Fiche T&#x000e9;cnica Ciproxina Simple 3 mg/L Gotas &#x000d3;ticas en Soluci&#x000f3;n.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/64940/FichaTecnica_64940.html">https://cima.aemps.es/cima/dochtml/ft/64940/FichaTecnica_64940.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-25">(accessed on 25 August 2020)</date-in-citation></element-citation></ref><ref id="B103-pharmaceutics-13-00387"><label>103.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>AEMPS</collab></person-group><article-title>CIMA</article-title><source>Fiche T&#x000e9;cnica Digoxina Kern Pharma 0.25 mg/mL Soluci&#x000f3;n Inyectable.</source><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cima.aemps.es/cima/dochtml/ft/34753/FT_34753.html">https://cima.aemps.es/cima/dochtml/ft/34753/FT_34753.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-25">(accessed on 25 August 2020)</date-in-citation></element-citation></ref><ref id="B104-pharmaceutics-13-00387"><label>104.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>FDA</collab></person-group><article-title>Abilify Solution Oral. Medication Guide</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021436s038,021713s030,021729s022,021866s023lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021436s038,021713s030,021729s022,021866s023lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-10">(accessed on 10 October 2020)</date-in-citation></element-citation></ref><ref id="B105-pharmaceutics-13-00387"><label>105.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>FDA</collab></person-group><article-title>Demerol Solution Oral. Medication Guide</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/005010s058lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/005010s058lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-10">(accessed on 10 October 2020)</date-in-citation></element-citation></ref><ref id="B106-pharmaceutics-13-00387"><label>106.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>DAILYMED</collab></person-group><article-title>DIAZEPAM SOLUTION, Lannett Company</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8cb8fe7-3744-41fa-8981-05a7fa8a2ec3">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8cb8fe7-3744-41fa-8981-05a7fa8a2ec3</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-16">(accessed on 16 October 2020)</date-in-citation></element-citation></ref><ref id="B107-pharmaceutics-13-00387"><label>107.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>FDA</collab></person-group><article-title>Adzenys ER Suspension, Extended Release; Oral. Medication Guide</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb1cc8d0-4231-41ea-8535-4fd872129713">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb1cc8d0-4231-41ea-8535-4fd872129713</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-16">(accessed on 16 October 2020)</date-in-citation></element-citation></ref><ref id="B108-pharmaceutics-13-00387"><label>108.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>DAILYMED</collab></person-group><article-title>Children&#x02019;s Tylenol&#x000ae; Cold Plus Cough Plus Sore Throat&#x02014;Acetaminophen and Dextromethorphan Hydrobromide Suspension</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e83f7911-22b4-4ffc-8f49-68f6acd2ebf5">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e83f7911-22b4-4ffc-8f49-68f6acd2ebf5</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-15">(accessed on 15 October 2020)</date-in-citation></element-citation></ref><ref id="B109-pharmaceutics-13-00387"><label>109.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>DAILYMED</collab></person-group><article-title>Dyanavel XR&#x02014;Amphetamine Suspension, Extended Release</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8a7eb93-4192-4826-bbf1-82c06634f553">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8a7eb93-4192-4826-bbf1-82c06634f553</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-15">(accessed on 15 October 2020)</date-in-citation></element-citation></ref><ref id="B110-pharmaceutics-13-00387"><label>110.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>DAILYMED</collab></person-group><article-title>Midazolam Hydrochloride Syrup</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0be63f63-6a93-4782-8f9c-d13ca5ae44bd">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0be63f63-6a93-4782-8f9c-d13ca5ae44bd</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-19">(accessed on 19 October 2020)</date-in-citation></element-citation></ref><ref id="B111-pharmaceutics-13-00387"><label>111.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>DAILYMED</collab></person-group><article-title>Ciprofloxacin and Dexamethasone Suspension/Drops</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f07cf7d6-c233-884e-342d-c6c8cd2c8438">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f07cf7d6-c233-884e-342d-c6c8cd2c8438</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-19">(accessed on 19 October 2020)</date-in-citation></element-citation></ref><ref id="B112-pharmaceutics-13-00387"><label>112.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>DAILYMED</collab></person-group><article-title>Allergy Eye Drops&#x02014;Ketotifen Fumarate Solution/Drops</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa9133fd-166e-4f05-9ca8-851ece692874">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa9133fd-166e-4f05-9ca8-851ece692874</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-19">(accessed on 19 October 2020)</date-in-citation></element-citation></ref><ref id="B113-pharmaceutics-13-00387"><label>113.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>DAILYMED</collab></person-group><article-title>Little Remedies Decongestant Nasal Drops&#x02014;Phenylephrine Hydrochloride Liquid</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8355eed-f1a2-4b4a-b65f-c2f4b28c12d1">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8355eed-f1a2-4b4a-b65f-c2f4b28c12d1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-19">(accessed on 19 October 2020)</date-in-citation></element-citation></ref><ref id="B114-pharmaceutics-13-00387"><label>114.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>DAILYMED</collab></person-group><article-title>BIO-G-TUSS PEDIATRIC DROPS&#x02014;Dextromethorphan HBR, Guaifenesin, Phenylephrine HCL Solution/Drops</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42045759-eaf2-4ffb-8a68-043f661acf8a">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42045759-eaf2-4ffb-8a68-043f661acf8a</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-19">(accessed on 19 October 2020)</date-in-citation></element-citation></ref><ref id="B115-pharmaceutics-13-00387"><label>115.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>DAILYMED</collab></person-group><article-title>Children&#x02019;s Motrin&#x02014;Ibuprofen Tablet, Chewable</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15b0b56d-6188-4937-b541-902022e35b24#footnote-1">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15b0b56d-6188-4937-b541-902022e35b24#footnote-1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-15">(accessed on 15 October 2020)</date-in-citation></element-citation></ref><ref id="B116-pharmaceutics-13-00387"><label>116.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>DAILYMED</collab></person-group><article-title>Acetaminophen Children&#x02019;s&#x02014;Acetaminophen Tablet, Chewable</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ce4f8cd-4a58-4c92-a8c1-c3cfhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ce4f8cd-4a58-4c92-a8c1-c3cfd591dba2d591dba2">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ce4f8cd-4a58-4c92-a8c1-c3cfhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ce4f8cd-4a58-4c92-a8c1-c3cfd591dba2d591dba2</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-15">(accessed on 15 October 2020)</date-in-citation></element-citation></ref><ref id="B117-pharmaceutics-13-00387"><label>117.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>DAILYMED</collab></person-group><article-title>Diazepam Tablet</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f226e5c1-9f6f-4bae-890d-ad4bdaeaf039">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f226e5c1-9f6f-4bae-890d-ad4bdaeaf039</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-16">(accessed on 16 October 2020)</date-in-citation></element-citation></ref><ref id="B118-pharmaceutics-13-00387"><label>118.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>DAILYMED</collab></person-group><article-title>Dexamethasone 1.5 MG&#x02014;Dexamethasone 1.5 mg Tablet</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcc75691-974e-4a67-b9d7-64dde72b5595">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcc75691-974e-4a67-b9d7-64dde72b5595</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-19">(accessed on 19 October 2020)</date-in-citation></element-citation></ref><ref id="B119-pharmaceutics-13-00387"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Der Vossen</surname><given-names>A.C.</given-names></name><name><surname>Van Der Velde</surname><given-names>I.</given-names></name><name><surname>Smeets</surname><given-names>O.</given-names></name><name><surname>Postma</surname><given-names>D.</given-names></name><name><surname>Eckhardt</surname><given-names>M.</given-names></name><name><surname>Vermes</surname><given-names>A.</given-names></name><name><surname>Koch</surname><given-names>B.C.P.</given-names></name><name><surname>Vulto</surname><given-names>A.</given-names></name><name><surname>Hanff</surname><given-names>L.</given-names></name></person-group><article-title>Formulating a poorly water soluble drug into an oral solution suitable for paediatric patients; lorazepam as a model drug</article-title><source>Eur. J. Pharm. Sci.</source><year>2017</year><volume>100</volume><fpage>205</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2017.01.025</pub-id><?supplied-pmid 28126558?><pub-id pub-id-type="pmid">28126558</pub-id></element-citation></ref><ref id="B120-pharmaceutics-13-00387"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Der Vossen</surname><given-names>A.</given-names></name><name><surname>Van Der Velde</surname><given-names>I.</given-names></name><name><surname>Smeets</surname><given-names>O.</given-names></name><name><surname>Postma</surname><given-names>D.</given-names></name><name><surname>Vermes</surname><given-names>A.</given-names></name><name><surname>Koch</surname><given-names>B.</given-names></name><name><surname>Vulto</surname><given-names>A.</given-names></name><name><surname>Hanff</surname><given-names>L.</given-names></name></person-group><article-title>Design and stability study of an oral solution of amlodipine besylate for pediatric patients</article-title><source>Eur. J. Pharm. Sci.</source><year>2016</year><volume>92</volume><fpage>220</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2016.05.019</pub-id><?supplied-pmid 27217083?><pub-id pub-id-type="pmid">27217083</pub-id></element-citation></ref><ref id="B121-pharmaceutics-13-00387"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gobetti</surname><given-names>C.</given-names></name><name><surname>Balsan</surname><given-names>M.E.</given-names></name><name><surname>Ayres</surname><given-names>M.V.</given-names></name><name><surname>De Almeida</surname><given-names>S.H.O.</given-names></name><name><surname>Simon</surname><given-names>E.D.S.</given-names></name><name><surname>Wingert</surname><given-names>N.R.</given-names></name><name><surname>Oppe</surname><given-names>T.P.</given-names></name><name><surname>Garcia</surname><given-names>C.V.</given-names></name></person-group><article-title>Development and Stability Control of Pediatric Oral Tizanidine Hydrochloride Formulations for Hospital Use</article-title><source>AAPS PharmSciTech</source><year>2020</year><volume>21</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1208/s12249-020-01751-8</pub-id></element-citation></ref><ref id="B122-pharmaceutics-13-00387"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Goede</surname><given-names>A.</given-names></name><name><surname>Boedhram</surname><given-names>R.</given-names></name><name><surname>Eckhardt</surname><given-names>M.</given-names></name><name><surname>Hanff</surname><given-names>L.</given-names></name><name><surname>Koch</surname><given-names>B.</given-names></name><name><surname>Vermaat</surname><given-names>C.</given-names></name><name><surname>Vermes</surname><given-names>A.</given-names></name></person-group><article-title>Development and validation of a paediatric oral formulation of clonidine hydrochloride</article-title><source>Int. J. Pharm.</source><year>2012</year><volume>433</volume><fpage>119</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2012.04.055</pub-id><?supplied-pmid 22580108?><pub-id pub-id-type="pmid">22580108</pub-id></element-citation></ref><ref id="B123-pharmaceutics-13-00387"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merino-Boh&#x000f3;rquez</surname><given-names>V.</given-names></name><name><surname>Delgado-Valverde</surname><given-names>M.</given-names></name><name><surname>Garc&#x000ed;a-Palomo</surname><given-names>M.</given-names></name><name><surname>D&#x000e1;vila-Pousa</surname><given-names>M.</given-names></name><name><surname>Ca&#x000f1;ete</surname><given-names>C.</given-names></name><name><surname>Villaronga</surname><given-names>M.</given-names></name><name><surname>Rodriguez-Marrod&#x000e1;n</surname><given-names>B.</given-names></name><name><surname>L&#x000f3;pez-Rojas</surname><given-names>R.</given-names></name><name><surname>Came&#x000e1;n-Fern&#x000e1;ndez</surname><given-names>M.</given-names></name><collab>The Pharmaceutical Technology Working Group and Pediatric Pharmacy Working Group of the Spanish Society of Hospital Pharmacy (SEFH)</collab></person-group><article-title>Physicochemical and microbiological stability of two new oral liquid formulations of clonidine hydrochloride for pediatric patients</article-title><source>Pharm. Dev. Technol.</source><year>2018</year><volume>24</volume><fpage>465</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1080/10837450.2018.1514520</pub-id><pub-id pub-id-type="pmid">30124097</pub-id></element-citation></ref><ref id="B124-pharmaceutics-13-00387"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopalco</surname><given-names>A.</given-names></name><name><surname>Curci</surname><given-names>A.</given-names></name><name><surname>Lopedota</surname><given-names>A.</given-names></name><name><surname>Cutrignelli</surname><given-names>A.</given-names></name><name><surname>Laquintana</surname><given-names>V.</given-names></name><name><surname>Franco</surname><given-names>M.</given-names></name><name><surname>Denora</surname><given-names>N.</given-names></name></person-group><article-title>Pharmaceutical preformulation studies and paediatric oral formulations of sodium dichloroacetate</article-title><source>Eur. J. Pharm. Sci.</source><year>2019</year><volume>127</volume><fpage>339</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2018.11.013</pub-id><pub-id pub-id-type="pmid">30447284</pub-id></element-citation></ref><ref id="B125-pharmaceutics-13-00387"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Provenza</surname><given-names>N.</given-names></name><name><surname>Calpena</surname><given-names>A.</given-names></name><name><surname>Mallandrich</surname><given-names>M.</given-names></name><name><surname>Sanchez</surname><given-names>A.</given-names></name><name><surname>Egea</surname><given-names>M.</given-names></name><name><surname>Clares</surname><given-names>B.</given-names></name></person-group><article-title>Permeation studies through porcine small intestine of furosemide solutions for personalised paediatric administration</article-title><source>Int. J. Pharm.</source><year>2014</year><volume>475</volume><fpage>208</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2014.08.059</pub-id><pub-id pub-id-type="pmid">25178830</pub-id></element-citation></ref><ref id="B126-pharmaceutics-13-00387"><label>126.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Kini</surname><given-names>R.S.</given-names></name><name><surname>Bhilegaonkar</surname><given-names>P.S.</given-names></name></person-group><article-title>Pharmaceutical Formulation Comprising Paracetamol Especially for Pediatrics</article-title><source>IN Patent</source><patent>201,721,007,863</patent><day>7</day><month>3</month><year>2017</year></element-citation></ref><ref id="B127-pharmaceutics-13-00387"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santove&#x000f1;a</surname><given-names>A.</given-names></name><name><surname>S&#x000e1;nchez-Negr&#x000ed;n</surname><given-names>E.</given-names></name><name><surname>Charola</surname><given-names>L.</given-names></name><name><surname>Llabr&#x000e9;s</surname><given-names>M.</given-names></name><name><surname>Farina</surname><given-names>J.B.</given-names></name></person-group><article-title>Study of quality and stability of ursodeoxycholic acid formulations for oral pediatric administration</article-title><source>Int. J. Pharm.</source><year>2014</year><volume>477</volume><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2014.10.011</pub-id><pub-id pub-id-type="pmid">25305380</pub-id></element-citation></ref><ref id="B128-pharmaceutics-13-00387"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santove&#x000f1;a</surname><given-names>A.</given-names></name><name><surname>Hern&#x000e1;ndez-Paiz</surname><given-names>Z.</given-names></name><name><surname>Fari&#x000f1;a</surname><given-names>J.</given-names></name></person-group><article-title>Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide</article-title><source>Int. J. Pharm.</source><year>2012</year><volume>423</volume><fpage>360</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2011.11.034</pub-id><pub-id pub-id-type="pmid">22155411</pub-id></element-citation></ref><ref id="B129-pharmaceutics-13-00387"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alayoubi</surname><given-names>A.</given-names></name><name><surname>Daihom</surname><given-names>B.</given-names></name><name><surname>Adhikari</surname><given-names>H.</given-names></name><name><surname>Mishra</surname><given-names>S.R.</given-names></name><name><surname>Helms</surname><given-names>R.</given-names></name><name><surname>Almoazen</surname><given-names>H.</given-names></name></person-group><article-title>Development of a taste-masked oral suspension of clindamycin HCl using ion exchange resin Amberlite IRP 69 for use in pediatrics</article-title><source>Drug Dev. Ind. Pharm.</source><year>2016</year><volume>42</volume><fpage>1579</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.3109/03639045.2016.1160102</pub-id><?supplied-pmid 26926148?><pub-id pub-id-type="pmid">26926148</pub-id></element-citation></ref><ref id="B130-pharmaceutics-13-00387"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goode</surname><given-names>G.A.</given-names></name><name><surname>Wagh</surname><given-names>S.J.</given-names></name><name><surname>Irby</surname><given-names>D.J.</given-names></name><name><surname>Ma</surname><given-names>D.</given-names></name><name><surname>Jacobs</surname><given-names>R.F.</given-names></name><name><surname>Kearns</surname><given-names>G.L.</given-names></name><name><surname>Almoazen</surname><given-names>H.</given-names></name></person-group><article-title>Bioavailability testing of a newly developed clindamycin oral suspension in a pediatric porcine model</article-title><source>Pharm. Dev. Technol.</source><year>2019</year><volume>24</volume><fpage>1038</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.1080/10837450.2019.1624771</pub-id><?supplied-pmid 31134840?><pub-id pub-id-type="pmid">31134840</pub-id></element-citation></ref><ref id="B131-pharmaceutics-13-00387"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suthar</surname><given-names>A.M.</given-names></name><name><surname>Patel</surname><given-names>M.M.</given-names></name></person-group><article-title>Suspension of Isoniazid Formulated Using Cationic Resin for Pediatric Use</article-title><source>Int. J. Curr. Pharm. Res.</source><year>2014</year><volume>6</volume><fpage>6</fpage><lpage>10</lpage><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://pdfs.semanticscholar.org/8c82/227ce826c2a063af50d4e90051a52ceb5285.pdf">https://pdfs.semanticscholar.org/8c82/227ce826c2a063af50d4e90051a52ceb5285.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-12-02">(accessed on 2 December 2020)</date-in-citation></element-citation></ref><ref id="B132-pharmaceutics-13-00387"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhuva</surname><given-names>F.</given-names></name><name><surname>Patel</surname><given-names>L.</given-names></name></person-group><article-title>Pediatric Nasal Spray Solution: Factorial Design Development and Evaluation</article-title><source>J. Drug Deliv. Ther.</source><year>2018</year><volume>8</volume><fpage>355</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.22270/jddt.v8i5-s.2067</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="pharmaceutics-13-00387-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Characteristics and advantages of ODT tablets.</p></caption><graphic xlink:href="pharmaceutics-13-00387-g001"/></fig><fig id="pharmaceutics-13-00387-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Disadvantages of ODT tablets.</p></caption><graphic xlink:href="pharmaceutics-13-00387-g002"/></fig><table-wrap id="pharmaceutics-13-00387-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-13-00387-t001_Table 1</object-id><label>Table 1</label><caption><p>Toxicity databases and public resources.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Website </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Creator </th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACToR &#x02014;Aggregated Computational Toxicology Resource </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><uri xlink:href="www.actor.epa.gov/actor/home.xhtml">www.actor.epa.gov/actor/home.xhtml</uri> (accessed on 15 November 2020)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">US Environmental Protection Agency&#x02019;s (EPA) National Center for Computational Toxicology (NCCT) </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STEP&#x02014;Safety and Toxicity of Excipients for Paediatrics *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><uri xlink:href="www.eupfi.org/step-database-info/">www.eupfi.org/step-database-info/</uri> (accessed on 15 November 2020)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">European Paediatric Formulation Initiative </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TOXNET&#x02014;Toxicology Data Network </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><uri xlink:href="www.nlm.nih.gov/toxnet/index.html">www.nlm.nih.gov/toxnet/index.html</uri> (accessed on 15 November 2020)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Specialized Information Services (SIS) USA </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitic </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><uri xlink:href="www.lhasalimited.org/products/vitic.htm">www.lhasalimited.org/products/vitic.htm</uri> (accessed on 2 November 2020) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lhasa Limited </td></tr></tbody></table><table-wrap-foot><fn><p>* The purposes of the STEP database can be consulted in the <xref ref-type="app" rid="app1-pharmaceutics-13-00387">Appendix A</xref>.</p></fn></table-wrap-foot></table-wrap></floats-group></article>